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Abstract 
Assessment and Prevention of Risk for Development of Cardiovascular Diseases in Geriatric Population with Chronic 
Kidney Disease  1 
ABSTRACT 
Chronic kidney disease is a large and growing problem among aging populations. The 
studies shows that the patients with chronic kidney disease are at increased risk of 
cardiovascular events even at early stage of kidney disease.Men are at increased risk of 
getting cardiovascular disease than women. The study was carried out to assess and prevent 
the cardiovascular risk in geriatric patients with chronic kidney disease getting admitted to 
the study site.  Study populations of 102 geriatric patients were included as per the inclusion 
criteria and data were collected in a specially designed data entry format. The collected data 
were screened to identify the cardiovascular risk in geriatric patients by using WHO risk 
scale, Framingham’s risk calculator and QRISK calculator. From the study it was found that 
diabetes mellitus and hypertension were the major problems may pose risk for cardiovascular 
disease in geriatrics. The present study had a various drugs prescribed for the study 
population including anti-hypertensives, anti-coagulants, anti-diabetics and proton pump 
inhibitors and diuretics. This study also revealed the importance of prevention of 
cardiovascular disease. The reasons for admission for the study population  was found to be  
difficulty in breathing, vomiting, decreased urine output, chest pain, etc. Route of 
administration for drug administered to the study population was analyzed and there was at 
least one drug administered as an injection to 83.33% patients. Length of stay for the study 
population in hospital was calculated and found that a minimum of 2 days and maximum of 
15 days. Analysis of drug – drug interaction’s prevalence in the study population revealed 
that 57% of the prescriptions do not have any such interactions. The core analysis of this 
work is assessment of CV risks in the geriatric study population with chronic kidney disease 
using three various scale that had revealed that 40% of the study population was in very high 
risk category and 20 & 32% were in high and moderate risk category respectively. The study 
population were counseled and intervened appropriately about various risks and its 
management to prevent themselves from entering into the next higher risk category.  
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1.INTRODUCTION
 
 
Anatomy and Physiology of  Kidney
1 
  
Fig.No.1:-Anatomy of kidney
1 
 
Every day the kidneys filter nearly 200 liters of fluid from the bloodstream, allowing 
toxins, metabolic wastes, and excess ions to leave the body in urine while returning needed 
substances to the blood. The bean-shaped kidneys lie in a retroperitoneal position (between 
the dorsal body wall and the parietal peritoneum) in the superior lumbar region. A frontal 
section through a kidney reveals three distinct regions :cortex, medulla, and pelvis. Nephrons  
are the structural and functional units of the kidneys. Each kidney contains over 1 million of 
these tiny blood-processing units, which carry out the processes that form urine. In addition, 
there are thousands of collecting ducts, each of which collects fluid from several nephrons 
and conveys it to the renal pelvis. Each nephron consists of a glomerulus, which is a tuft of 
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capillaries, and a renal tubule. The renal tubule has a cup-shaped end, the glomerular 
capsule(or Bowman’s capsule), which is blind and completely surrounds the glomerulus. 
Collectively, the glomerular capsule and the enclosed glomerulus are called the renal 
corpuscle
1
. The detailed diagram is shown in Fig.no.1. 
 
Kidney Diseases 
Kidney diseases are classified into two:Acute kidney disease and chronic kidney 
disease.Acute renal failure (ARF) is a common and serious problem in clinical medicine. It is 
characterised by an abrupt reduction (usually within a 48-h period) in kidney function
2
.  It is 
also a condition in which a previously normal serum creatinine rises by 0.5 mg/dL, or an 
absolute increase in serum creatinine of >1 mg/dL in a patient
3
. 
Chronic kidney disease (CKD) is a reduction in the glomerular filtration rate (GFR) 
and/or urinary abnormalities or structural abnormalities of the renal tract2.The name chronic 
kidney disease was proposed by the National Kidney Foundation–Kidney Disease Quality 
Outcome Initiative (K/DOQI) as a way of simplifying and codifying the language used to 
communicate about the disease. CKD is also defined as either of the following conditions i.e 
for a minimum of 3 months: glomerular filtration rate (GFR) less than 60 mL/min/1.73 m
2
, or 
damage to the kidney(s) with or without a decrease in GFR. This damage may be evidenced 
by abnormalities in the composition of blood or urine, or by changes seen in imaging studies. 
The K/DOQI Working Group further categorizes the extent of kidney disease according to 
the presence of kidney damage and the GFR. Stage I CKD is defined as the presence of 
kidney damage even though GFR may be normal or elevated as ≥90 mL/min/1.73 m2. Stage 
II CKD is evidenced by a GFR between 60 and 89 mL/min/1.73 m2. Patients with Stage III 
CKD may or may not have kidney damage, while their GFR is reduced to between 30 and 59 
mL/min/1.73 m2. CKD patients with Stage IV disease also may not have intrinsic kidney 
damage, but their GFR is severely reduced to between 15 and 29 mL/min/1.73 m2. The last 
stage, Stage V, is also known as end-stage kidney disease (ESKD). This condition, formerly 
known as end-stage renal disease (ESRD) which is defined as a GFR less than 15 
mL/min/1.73 m
2
 or the need for renal replacement therapy (RRT) for survival. The Tab.No.1 
will give a detailed description of CKD. 
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Most forms of kidney disease will cause irreversible, progressive deterioration of 
kidney function if not identified and treated properly. Depending on the cause, the disease 
may progress to complete loss of function over months to years. As the extent of deterioration 
increases, the kidney is unable to perform normal homeostatic functions. This leads to fluid 
and electrolyte abnormalities, acid-base disturbances, hormonal dysregulation, and other 
systemic disturbances. When the GFR falls to below 15 mL/min/1.73 m2, patients generally 
require some form of RRT for survival. Options for RRT include hemodialysis, peritoneal 
dialysis, and kidney transplantation. Although patients may be maintained on dialysis or may 
receive a kidney transplant but they have increased risks of morbidity and mortality
4
.  
Tab.No.1:-Classification of Chronic Kidney disease
4 
Classification Damage 
GFR 
(ml/min.) 
Increased risk of kidney 
disease 
Risk factors for CKD(diabetes,HTN,family 
history of CKD) 
≥90 
Stage 1 Kidney damage with normal GFR ≥90 
Stage II Kidney damage with mild decrease in GFR 60-89 
Stage III Moderate decrease in GFR 30-59 
Stage IV Severe decrease in GFR 15-29 
Stage V Kidney failure <15 
CKD-chronic kidney disease; GFR-glomerular filtration rate; HTN-hypertension 
 
Renin-angiotensin-aldosterone system
2 
 
The renin-angiotensin-aldosterone system (RAAS) has a critical role in the 
progression of CKD and an awareness of this system is important for understanding the 
pathophysiology of CKD and the targets for therapeutic intervention. Most of the renal 
effects of this system are through regulating intraglomerular pressures, salt and water 
balance. Renin is an enzyme which is formed and stored in the juxtaglomerular apparatus and 
released in response to decreased afferent intra-arterial pressures, decreased glomerular 
ultrafiltrate sodium levels and sympathetic nervous system activation. In patients with CKD, 
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intra-renal pressures are often low and sympathetic over activity is common; these factors 
lead to increased renin secretion. This can occur with normal or elevated systemic blood 
pressure.Renin promotes cleavage of the protein angiotensinogen, which is produced by the 
liver, to produce angiotensin I. Angiotensin I is converted to angiotensin II by angiotensin 
converting enzyme (ACE). Angiotensin II has two major physiological effects. First, it acts 
on the zona glomerulosa ofthe adrenal cortex to promote production of the mineralocorticoid 
hormone aldosterone, with resultant increased distal tubular salt and water reabsorption. 
Furthermore, it promotes antidiuretic hormone (ADH) release, which increases proximal 
tubular sodium reabsorption and promotes thirst. In combination, these lead to salt and fluid 
retention, high intravascular volumes, hypertension and oedema. Second, it is a direct 
vasoconstrictor and promotes systemic and (preferential) renal hypertension. The renal 
effects are predominantly on the efferent glomerular arteriole. Vasoconstriction at this site is 
mediated by a high density of angiotensin II receptors. When these receptors are ligated by 
angiotensin II, there is increased intra- glomerular pressures. Whilst this leads to an overall 
increase in GFR in the short-term, over a longer period glomerular hypertension promotes 
accelerated glomerular scarring and worsening CKD. In addition to the vascular and 
endocrine effects of the RAAS, it is now recognised that there is a local immune modulatory 
role for this system. Both resident (e.g. tubular epithelial) cells and inflammatory (monocytes 
and macrophages) cells synthesis components of the RAAS and are themselves targeted by 
the system. The RAAS is depicted in the following Fig.No.2 
 
Causes of CKD
2 
The reduction in renal function observed in CKD results from damage to the infrastructure of 
the kidney in discrete areas. The nephron is the functional unit of the kidney, as nephrons 
become damaged and fail, remaining nephrons compensate for loss of function by 
hyperfiltration secondary to raised intra-glomerular pressure. This causes damage with 
secondary nephron loss. The patient remains well until so many nephrons are lost that the 
GFR can no longer be maintained despite the activation of compensatory mechanisms. As a 
consequence there is a progressive decline in kidney function.CKD arises from a variety of 
causes which are listed in Tab.No.2 are ordered according to prevalence. It is important to 
note the prevalence of these factors are different in CKD and end stage renal disease.CKD 
arises from a variety of causes such as Glomerulonephritis, Pyelonephritis, Diabetes, 
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Polycystic kidney and hypertension. Renal vascular disease although by the time a patient has 
established CKD it may not be possible to identify the exact cause. 
Fig.No.2:-Renin angiotensin –aldosterone system2 
 
 
 
Tab.No.2: – Causes of CKD2 
Primary diagnosis Overall% 
Uncertain aetiology 21.6 
Glomerularnephritis 15.3 
Pyelonephritis 11.9 
Diabetes 13.4 
Polycystic kidney 9.2 
Hypertension 5.4 
Renal vascular disease 3.2 
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Pathophysiology
3
 
                The presence of or exposure to the initiation risk factors results in loss of nephron 
mass. The remaining nephrons compensate for the loss of renal function and nephron mass. 
Initially this compensatory hypertrophy may be adaptive. Yet over time the hypertrophy often 
becomes maladaptive and leads to the development of glomerular hypertension, possibly 
mediated by angiotensin II which is a potent vasoconstrictor of both the afferent and efferent 
arterioles, preferentially affects the efferent arterioles, leading to increased pressure within 
the glomerular capillaries. The development of intraglomerular hypertension generally 
correlates with the development of systemic arterial hypertension. The resultant proteinuria is 
thought to accelerate the progressive loss of nephrons due to direct cellular damage. The 
filtered proteins consist of albumin, transferrin, complement factors, immunoglobulin, 
cytokines, and angiotensin II, which have varying molecular weights. The pathophysiology is 
shown in Fig.No.3 as a schematic representation. Numerous studies have demonstrated that 
the presence of these proteins in the renal tubule activate tubular cells which leads to the 
unregulated production of inflammatory and vasoactive cytokines, such as endothelin, 
monocyte chemoattractant protein (MCP-1), and RANTES (regulated upon activation, 
normal T-cell expressed and secreted) 
 
Fig.No.3:- Pathophysiology of chronic kidney disease.
3 
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Measurement of renal function
2 
The GFR is defined as the volume of filtrate produced by the glomeruli of both 
kidneys every minute and is a reliable indicator of renal function. It is expensive to measure 
GFR by gold standard tests such as inulin or radiolabelled isotope clearance. These tests are 
only used when extremely accurate assessment of kidney function is required. There are 
equations which can provide an estimate of glomerular filtration rate (eGFR) based on the 
combination of serum or plasma creatinine. The commonest eGFR equation used in clinical 
practice is the four-variable MDRD (Modification of Diet in Renal Disease Study) equation. 
The biochemical variable that provides the basis of the MDRD and most other GFR equations 
is serum creatinine. 
 
Serum creatinine: Measurement of serum creatinine can be utilised to give an estimate of 
the kidney function. It is important to note, however, that creatinine also undergoes 
significant tubular secretion (~10–20%). This becomes important in advanced CKD (stages 4 
and 5) and limits the value of measuring serum creatinine to determine renal function in 
advanced CKD. 
 
MDRD glomerular filtration rate equation: The MDRD equation is more accurate than 
serum creatinine alone as an estimator of kidney function; those with creatinine levels within 
the normal range or transplant recipients. The CKD classification system is based on the 
MDRD eGFR.
 
 
 
 
 
Cockroft–Gault equation: The Cockroft–Gault equation uses weight, sex and age to 
estimate creatinine clearance and was derived using average population data. 
 
 
 
 
ClCr =    F (140 age (years)) x weight (kg) 
              Serum creatinine (mol/L) 
             where F = 1.04 (females) or 1.23 (males) 
eGFR (mL/min/1.73m2) = 186 x [serum creatinine (μmol/L)/88.4]–1.154 x [age]–0.203 x 
[0.742 if female] x [1.212 if African-American] 
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Creatinine clearance: It is a measurement of the volume of blood that is cleared of 
creatinine with time. Measurements of creatinine clearance (ClCr) require accurate collection 
of 24 h urine samples with a serum creatinine sample midway through this period. 
 
 
 
 
 
 
 
Clinical Presentation of Chronic Kidney Disease
3
 
CKD development and progression is typically insidious in onset, often with the 
absence of any noticeable symptoms. At a minimum, the diagnosis of CKD requires 
measurement of serum creatinine, calculation of GFR and assessment of a urinalysis for 
urinary microalbumin or total protein. The diagnosis of Stages 3, 4, and 5 CKD requires the 
work-up for other common complications including anemia, cardiovascular risks, metabolic 
bone disease, malnutrition, and disorders of fluids and electrolytes. 
 
SIGNS AND SYMPTOMS
 
Symptoms are generally absent in CKD Stages 1 and 2, and may be minimal during 
Stages 3 and 4. Classic symptoms associated with Stage 5 CKD include pruritus, dysgeusia, 
nausea, vomiting and bleeding abnormalities. Symptoms associated with anemia include cold 
intolerance, shortness of breath, and fatigue. The severity of symptoms are related to the rate 
of anemia development and the degree of haemoglobin reduction.The following signs shall 
be observed during CKD. 
 
Cardiovascular: Leftventricular hypertrophy, congestive heart failure, 
hyperhomocysteinemia, dyslipidemia, palpitations, arrhythmias, electrocardiographic 
changes, elevated creatinekinase-myocardial bound (CK-MB) and creatine kinase (CK), 
worsening hypertension, and oedema. 
Musculoskeletal: Cramp and muscle pain. 
Neuropsychiatric: Depression, anxiety, impaired mental cognition, fatigue, and sexual 
dysfunction. 
ClCr =     U x V 
            S 
where U is the urine creatinine concentration 
(μmol/L), V is the urine flow rate (mL/min) and 
S is the serum creatinine concentration 
(μmol/L) 
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Gastrointestinal: Gastroesophageal reflux disease, constipation,GI bleeding, nausea, and 
vomiting. 
 
Laboratory Investigations 
Structural assessments of the kidney may be performed using a number of imaging 
procedures, including ultrasonography, intravenous urography (IVU), plain abdominal 
radiography, computed tomography (CT), magnetic resonance imaging (MRI) and magnetic 
resonance angiography (MRA). 
Treatment
1 
The overall aims of the treatment of CKD can be summarized as follows: 
• Reverse or arrest the process causing the renal damage (this may not be possible) 
• Avoid conditions that might worsen renal failure 
• Treat the secondary complications of CKD (renal anaemia and bone disease) 
• Relieve symptoms 
• Implement regular dialysis treatment and/or transplantation at the most appropriate 
time. 
Treatment of Diabetic Nephropathy 
Diabetic nephropathy is caused mainly by the presence of hyperglycemia, as 
previously discussed. In this situation, the best way to prevent or slow renal damage is to 
prevent hyperglycemia. 
Treatment of Hypertension with Antihypertensive Agents 
The following treatment strategies are used: decrease blood pressure to less than 
130/80 mm Hg, reduce proteinuria, slow progression of kidney disease and reduce CVD risk. 
Some of antihypertensive drugs used for the treatment of CRF is given in following 
Tab.No.3. 
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Tab.No.3:- Treatment  of hypertension
3
 
Effects of antihypertensive agents on renal blood flow(RBF) and glomerular filtration 
rate(GFR) 
Antihypertensive agent Mechanism of action 
Effects on renal 
hemodynamic 
 
 
Diuretics  
Sodium and volume depletion Decrease in GFR and RBF 
Increase vasodilatory 
prostaglandin levels 
Increase in RBF 
Renal vasoconstriction Decrease in GFR and RBF 
 
 
Β-adrenergic blockers 
Decrease cardiac output Decrease in GFR and RBF 
Increase renal vascular 
resistance (nonselective agents) 
Decrease in GFR and RBF 
Decrease vascular resistance 
(β-selective agents) 
No change in GFR and RBF 
Centrally acting antiadrenergic 
drugs 
Decrease renal vascular 
resistance 
No change in GFR and RBF 
↓ Renal perfusion pressure 
(clonidine, α2-adrenergic 
agonist) Decrease in GFR and 
RBF 
↓ Renal perfusion pressure 
(clonidine, α2-adrenergic 
agonist) Decrease in GFR and 
RBF 
Peripherally acting 
antiadrenergic 
Peripherally acting 
antiadrenergic 
Peripherally acting 
antiadrenergic 
 
 
 
Direct vasodilator agents 
↓ Renal vascular resistance 
(hydralazine, minoxidil) 
Increase in RBF and no effect 
on GFR 
Direct vasodilator agents ↓ 
Renal vascular resistance 
(hydralazine, minoxidil) 
Increase in RBF and no effect 
on GFR 
Arterial vasodilation plus 
dilatation of venous 
capacitance 
Arterial vasodilation plus 
dilatation of venous 
capacitance 
Angiotensin-converting enzyme Angiotensin-converting 
enzyme 
Angiotensin-converting 
enzyme 
Calcium channel blockers ↓ 
Renal vascular resistance by 
vasodilation of afferent 
↓ Renal vascular resistance by 
vasodilation of afferent 
↓ Renal vascular resistance by 
vasodilation of afferent 
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Treatment of Proteinuria
4 
 
Lowering the total daily protein excretion in the urine and the use of different agents 
were used to achieve this goal. As previously mentioned, protein is the specific target for 
treatment. Several strategies have been tried to decrease proteinuria and therefore decrease 
the rate of decline to ESRD, as well as to reduce morbidity and mortality. The treatment 
algorithm for protein urea is depicted in the following Fig.No.4. 
Fig.No.4:-Treatment of proteinuria
4 
 
ACE-I, angiotensin-converting enzyme inhibitor; ARB, angiotensin receptor blocker; 
BP, blood pressure; DHCCB, dihydropyridine calcium channel blocker; Na, sodium; 
NDH-CCB, nondihydropyridine calcium channel blocker; NSAIDs, nonsteroidal anti-
inflammatory drugs. 
 
  
Level 1
• Control BP
• Provide ACE-I therapy
• Administer ARB 
treatment
• Provide combination 
ACE-I and ARB
• Avoid DHCCB
• Provide β-blocker 
therapy
• Control protein intake
Level 2
• Restrict Na intake
• Control fluid intake
• Provide NDH-CCB 
therapy
• Control lipids
• Administer an 
aldosterone antagonist
• Assist with smoking 
cessation
• Avoid estrogen/progestin
Assume 
supine/recumbent 
position
Reduce obesity
Level 3
• Decrease homocysteine 
level
• Give antioxidant therapy
• Use sodium bicarbonate 
for metabolic acidosis
• Give NSAIDs for 
nephrotic syndrome
• Other (avoid iron 
overload, intake of 
caffeine, etc.)
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Treatment of Dyslipidemia 
The benefits of treating dyslipidemia in patients with CKD have been demonstrated 
through many studies. Specifically, studies suggest that hydroxymethylglutaryl coenzyme A 
reductase inhibitors (HMG-CoA, statins) are particularly beneficial. Statins may decrease 
proliferation of mesangialand proximal tubular cells, reducing glomerulosclerosis. The 
treatment guidelines of dyslipidemia is given below Tab.No.4  
Tab.No.4:- Treatment Guidelines for Dyslipidemias of CKD
4  
Dyslipidemia Goal Initiate Increase Alternative 
TG ≥500 mg/dL <500 TLC Fibrate or niacin Fibrate or niacin 
LDL 100–129 <100 TLC Low-dose statin Bile acid seq or 
niacin 
LDL ≥130 <100 TLC + low-dose 
statin 
Max-dose statin Bile acid seq or 
niacin 
TG ≥200 and 
non-HDL ≥130 
Non-HDL <130 TLC < low-dose 
statin 
Max-dose statin Fibrate or niacin 
CKD, chronic kidney disease; HDL, high-density lipoprotein; LDL, low-density 
lipoprotein; seq, sequestrants; TG, triglycerides; TLC, therapeutic lifestyle changes. 
 
Consequences Of CKD
2 
CKD is significant as it indicates the possibility of progression to end-stage renal 
disease, and a strong association with accelerated cardiovascular disease. The cardiovascular 
risk increases with the severity of CKD but is detectable at all levels. Thus, it is important to 
pay particular attention to cardiovascular risk factors such as smoking, cholesterol and blood 
pressure in patients with CKD. However, it is known from previous studies that these risk 
factors only contribute around 50% of the total cardiovascular disease risk. It is important to 
make a distinction between cardiovascular disease related to macrovascular atherosclerosis 
and that related to microvascular changes, often found in individuals with CKD. The 
cardiovascular disease found in CKD is more likely to be related to small vessel disease 
initiated by endothelial dysfunction rather than atherosclerotic disease. In addition, patients 
with CKD often have associated left ventricular hypertrophy which may be related to chronic 
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volume overload and uraemia. Progression to more advanced stages of CKD may occur, 
particularly if the blood pressure is inadequately controlled and there is significant 
proteinuria, but this is by no means the rule and many patients with CKD remain stable for 
years or even decades. These patients need to be followed up with regular blood and urine 
tests to detect progression, if it occurs. Low risk patients, that is, those with unchanging GFR 
over time, with controlled blood pressure and no proteinuria may not require long-term 
follow up by a kidney specialist and surveillance can be carried out satisfactorily in primary 
care. Patients with CKD 1–3 are frequently asymptomatic. The reduction of GFR is 
insufficient to cause uraemic symptoms and any minor abnormalities in the urine such as 
proteinuria or haematuria are usually not noticed by patients. There is a frequent association 
with high blood pressure which may be the cause or a consequence of renal damage.Patients 
with CKD stages 4 and 5 should usually be followed up in a nephrology clinic because they 
will require specialist management of the complications of CKD such as anaemia and bone 
disease, whilst many will also be undergoing preparation for renal replacement therapy. 
 
Cardiovasular Risk 
Cardiovascular disease (CVD) is responsible for the majority of deaths in chronic 
renal failure (CRF).The report showed that there was a high prevalence of CVD in CKD and 
that mortality due to CVD was 10 to 30 times higher in dialysis patients than in the general 
population
5
. There is a direct relationship between the degree of kidney dysfunction and 
cardiovascular risk (CVR). The presence of proteinuria or microalbuminuria is a strong CVR, 
while the main causes of kidney diseases are diabetic nephropathy and hypertensive 
nephrosclerosis, accelerated by smoking and dyslipidemia. Thus, increased CVR among 
patients with CKD is secondary to the accumulation of these risk factors. CVR factors 
include: hypertension, dyslipidemia, presence of left ventricular hypertrophy,obesity, diabetes 
mellitus (DM) and some lifestyle- related habits (high-calorie diet, saturated fats, high 
cholesterol, salt, alcohol consumption, smoking and sedentariness).In addition tothese, there 
are non-traditional CVR factors, such as inflammation, oxidative stress, persistentinfection, 
proteinuria and hyperphosphatemia.
2
 
1. Hypertension: Hypertension results in atherosclerosis which can cause occlusive 
renovascular disease and small vessel damage. In patients with significant large vessel 
occlusive disease arteriolar nephrosclerosis, interstial fibrosis and glomerular collapse 
may be present. These diagnoses account for around 30% of CKD and a smaller 
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proportion of end stage renal disease. The effective management of hypertension is 
crucial to reduce renal damage. 
2. Diabetes: Diabetes mellitus is the most common metabolic disease that leads to CKD, 
whilst the predominant lesion in glomerular and referred to as diabetic nephropathy. 
Diabetes accounts for around 13% of CKD and is associated with faster renal 
deterioration than other pathologies: these patients are at very significant 
cardiovascular risk by virtue of both CKD and diabetes. Patients with diabetes may 
present with no proteinuria, micro albuminuria or overt proteinuria, though as the 
level of proteinuria increases the GFR usually declines and in many patients this 
represents an inexorable decline towards end stage renal disease. 
3. Chronic glomerularnephritis: All types of chronic glomerulonephritis (GN) 
combined cause about 15% of cases of advanced CKD. The commonest cause of 
glomerulonephritis is IgA nephropathy which is characterised by deposition of 
polymeric IgA in the glomerulus with subsequent immune activation. Other patterns 
of glomerulonephritis include membranous nephropathy, where there is granular 
deposition of immunoglobulin on the glomerular capillary basement membrane. 
Systemic autoimmune diseases such as systemic lupus erythematosus can cause a 
variety of types of glomerulonephritis. 
 
               The incidence of drug-induced nephrotoxicity has been increasing with the ever 
increasing number of drugs and with easy availability of over-the-counter medication viz. 
nonsteroidal anti-inflammatory drugs (NSAIDs),Antibiotics, angiotensin converting enzyme 
inhibitors (ACEI) and contrast agents are the major culprit drugs contributory to kidney 
damage. Drug-induced acute renal failure (ARF) accounted for 20% of all ARF in an Indian 
study; of which aminoglycosides accounted for 40% of total cases
6
. 
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2. Scope of the Study 
Recent findings from the global burden of disease (GBD) 2010 and 2013, studies have 
highlighted CKD as an important cause for global mortality. The number of deaths from 
CKD was estimated to be 9,56,200 in 2013, a 37 % increase from 1990, one of the largest 
increases among the top 50 causes of deaths, behind HIV/AIDS and diabetes. Thus, kidney 
disease constitutes a global public health priority, also underlined by the fact that worldwide 
the prevalence of end-stage renal disease (ESRD) patients receiving renal replacement 
therapy (RRT) with maintenance dialysis has increased 1.7 times from 165 patients per 
million population (pmp) in 1990 to 284 pmp in 2010. Moreover, it has been estimated that 
the projected number of people receiving RRT (dialysis or transplantation) will be more than 
double from 2618 million people worldwide in 2010 to 5436 million in 2030. Notably, 
between 2284 and 7083 million people who could have been kept alive with RRT in 2010 
who had died prematurely because they did not have access to the treatment
11
. 
 
Chronic kidney disease (CKD) is a major public health problem.CKD was defined by 
a GFR < 60 ml/min per 1.73 m
2
.In dialysis patients, cardiovascular disease (CVD) mortality 
rates are 10 to 30 times higher than in the general population. In high-risk patients, defined by 
the presence of either CVD or cardiovascular risk factors, less severe kidney disease is also 
an independent risk factor for CVD outcomes. Data from some studies suggest the absence of 
an independent association between the presence of CKD and CVD, whereas other data 
suggest that CKD is an independent risk factor for CVD outcomes
5
. 
 
The manifestations of cardiovascular disease in patients with chronic kidney disease 
are diverse. Studies have shown that even patients with mild kidney disease are at greatly 
increased risk for cardiovascular events.CVD and CKD have complex interactions and may 
produce metabolic imbalances such as chronic inflammation ,erythropoietin deficiency 
resulting anemia and metabolic disorder
8
. 
 
The higher death risk associated with CKD reflects higher rates of atherosclerotic 
vascular disease and congestive heart failure has clinical relevance. Kidney disease and 
cardiovascular disease both are approaching epidemic levels in the elderly. Both conditions 
seem to be lethally synergistic
9
. About 1 in 10 people have some degree of CKD. It can 
develop at any age and various conditions can lead to CKD. 
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It is estimated that about one in five men and one in four women between the ages of 
65 and 74, and half of people aged 75 or more have CKD. In short, the older you get the more 
likely you are to have some degree of kidney disease. This is important because CKD 
increases the risk of heart attack and stroke, and in some cases can progress to kidney failure 
requiring dialysis or transplantation. Regardless of your age, simple treatments can slow the 
progression of kidney disease, prevent complications and improve quality of life
10
.All stages 
of CKD are associated with increased risks of cardiovascular morbidity, premature mortality, 
and/or decreased quality of life. CKD is usually asymptomatic until later stages and accurate 
prevalence data are lacking. 
 
Global mean of CKD prevalence of 5 stages were given as 13·4%, and stages III–V 
was 10·6%. CKD prevalence by stage was Stage I- 3·5% Stage II- 3·9%, Stage III-7·6%,     
Stage IV- 0·4% and Stage V- 0·1%. CKD has a high global prevalence with a consistent 
estimated global CKD prevalence of between 11 to 13% with the majority stage 3
11
. 
 
Kidney disease can affect people of all ages and races. African Americans, Hispanics, 
American Indians and people of South Asian origin (those from India, Bangladesh, Sri Lanka 
or Pakistan) have a higher risk of CKD. This risk is due in part to high rates of diabetes and 
high blood pressure in these communities.CKD can occur at any age, but becomes more 
common with increasing age. Although about half of people aged 75 or more have some 
degree of CKD, many of these people do not actually have diseases of their kidneys; they 
have normal ageing of their kidneys. Simple blood and urine tests can detect CKD and 
simple, low cost treatments can slow the progression of the disease, reduce the risk of 
associated heart attacks and strokes and improve quality of life.10% of the population 
worldwide is affected by chronic kidney disease (CKD), and millions die each year because 
they do not have access to affordable treatment
10
.According the 2010 Global Burden of 
Disease study, chronic kidney disease was ranked 27
th
 in the list of causes of total number of 
deaths worldwide in 1990, but rose to 18
th
 in 2010. This degree of movement up the list was 
second only to that for HIV and AIDs
12
. Over 2 million people worldwide currently receive 
treatment with dialysis or a kidney transplant to stay alive, yet this number may only 
represent 10% of people who actually need treatment to live
13
. After the age of 40, kidney 
filtration begins to fall by approximately 1% per year. On top of the natural aging of the 
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kidneys, many conditions which damage the kidneys are more common in older people 
including diabetes, high blood pressure and heart disease. 
Chronic Kidney Disease (CKD) is one of the major causes of death in India. 
Hypertension and Diabetes Mellitus are the common causes of CKD. Two studies showed 
significant correlation between CKD and age, Diabetes Mellitus, hypertension, serum 
creatinine. One study showed 23.5% of hypertensive subjects were having CKD stage III. 
Every year1,00,000 newly diagnosed patients of end stage renal disease (ESRD) start dialysis 
in India .From India limited data are available about the prevalence of CKD. In India diabetes 
and hypertension account for 40-60% cases of CKD.  With increasing prevalence of these 
diseases in India, prevalence of CKD is expected to increase, and obviously this is the key 
target population to address. Identification of CKD in early stages is important to delay the 
progression of the disease which intern decreases the economic burden on individual, family 
and community. More such studies are required to sensitize the people about the functioning 
of kidney
14
. 
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3. LITERATURE REVIEW 
 
1. Bogdan Ene-Iordache et al did a crosssectional study on chronic kidney disease and 
cardiovascular risk in six regions of the world (ISN-KDDC). The study was 
conducted in 12 countries from six world regions: Bangladesh, Bolivia, Bosnia and 
Herzegovina, China, Egypt, Georgia, India, Iran, Moldova, Mongolia, Nepal, and 
Nigeria. Risk of cardiovascular disease development was estimated with the 
Framingham risk score. The number of participants at high risk of cardiovascular 
disease, according to the Framingham risk score, was underestimated compared with 
KDIGO guidelines. For example, all individuals with chronic kidney disease should 
be considered at high risk of cardiovascular disease, but the Framingham risk score 
detects only 23% in the general population, and only 38% in high-risk cohorts
15
. 
 
2. Yuichi Ikeda et al did a study on GDF15 [Growth differentiation factor] as a relative 
biomarker for cardiovascular risk assessment. The study shows GDF15 levels serve as 
an independent predictor of major cardiovascular diseases in Japanese patients with 
Acute Myocardial Infarction [AMI]. They had also reported that further studies are 
required to understand the pathophysiological roles in various cardiovascular 
diseases
16
 
 
3. Steven C.Lin et al did a clinical trial study on cardiovascular risk assessment in the 
treatment of NASH [Non-Alcoholic Steatohepatitis] a secondary analysis of the 
MOZART [Magnetic Resonance Imaging and elastography in ezetimibe] for the 
assessment of response to treatment in NASH. The study was concluded that 
ezetimibe improved Framingham Risk Score and coronary artery calcification score 
which indicated the feasibility of monitoring CV risk in NASH trial as there were no 
much trials conducted 
17
. 
 
4. Silvio E Inzucchi et al did a study on SGLT-2 [Sodium Glucose Co Transporter -2] 
Inhibitors and cardiovascular risk. The study revealed that cardiovascular risk was 
increased due to control Type2 Diabetes Mellitus and better glycaemic control was 
the lead factor. The study concluded that SGLT-2are novel oral glucose lowering 
agents and it reduce hyperglycemia in patients with T2 Diabetes Mellitus 
18
. 
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5. Vivian K. Kawai et al did a cross-sectional study in rheumatoid arthritis patients 
having increased cardiovascular risk. Coronary Artery Calcification have been 
increased in rheumatoid arthritis patients. The ACC/AHA risk score does not offer 
any advantage compared to the traditional FRS & RRS in identifying the risks in RA 
patients and it assigned almost 60% of patients with CAC to a low risk category. Risk 
scores and standard risk prediction models used in population which can’t identify 
many RA patients with elevated cardiovascular risk 
[19]
. 
 
6. Nisha Bansal et al done a prospective study on blood pressure and risk of all-cause 
mortality in advanced chronic kidney disease and hemodialysis - the chronic renal 
insufficiency cohort study. They studied the association between SBP and mortality 
when participants (1) had an estimated glomerular filtration rate <30ml/min/1.73m
2
 
(n=1705),(2) initiated hemodialysis and had dialysis – unit SBP measures and 
(3)initiated haemodialysis and had out-of-dialysis-unit SBP measured at a chronic 
renal insufficiency cohort study visit. At advanced chronic kidney disease, there was 
no association between SBP and mortality. Among participants who started 
hemodialysis, a U-shaped association between dialysis-unit SBP and mortality was 
observed. In contrast, there was a linear association between out-of-dialysis-unit SBP 
and mortality. In conclusion, more efforts should be made to obtain out-of-dialysis-
unit SBP, which may merit more consideration as a target for clinical management 
and in interventional trials
20
. 
 
7. Paul M Ridker et al did an epidemiological study on High sensitivity C-reactive 
protein for Global risk assessment in the primary prevention of cardiovascular 
diseases and the protein’s presence in plasma is the main risk and also a predictor for 
myocardial infraction, stroke, and vascular death in individuals without known 
cardiovascular disease. Overall increase in high sensitivity C-reactive protein 
increases the relative risk of suffering future cardiovascular event for both men and 
women 
21
. 
 
8. J J Brugts et aldid a meta-analysis of randomized control clinical trial to understand 
the benefits of statins in people without established CVD but with CV risks. The 
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study concluded that patients without established cardiovascular disease but with 
cardiovascular risk factors use of statin and if had improved the survival and found to 
have a large reduction in the risk of cardiovascular events 
22
 
 
9. C W Siu et al did a study on pre-operative cardiac risk assessment in geriatric patients 
with hip fractures. The study revealed that risk assessment helps in not only 
identifying high risk patient before their operation and also reduces the unnecessary 
cardiac consultation for low risk patients 
23
. 
 
10. Tanja Zeller et al did a study in high population of cardiac troponin I measured by a 
high sensitivity assay and cardiovascular risk estimation. The results provided 
evidence that high sensitive assayed troponin I is a cardiac-specific marker of global 
cardiovascular risk. It may reflect pathophysiological progression from myocardial 
health to myocardial damages 
24
. 
 
11. Cláudia Bernardi Cesarino et al assessed the cardiovascular risk in patients with 
chronic kidney disease according to Framingham’s criteria in a cross-sectional study 
with a sample of 242 patients with chronic kidney disease. The most prevalent risk 
factors for cardiovascular disease were: hypertension, sedentariness and smoking. 
Cardiovascular risk in relation to the variables gender and family income presented a 
statistical difference (p<0.05).This data showed low cardiovascular risk in patients 
with chronic kidney disease
25.
 
 
12. Manish Bansal et al did a comparative study to differentiate risk scores in assessing 
cardiovascular risk in Indian patients with first myocardial infraction.  Risk [WHO] 
underestimates the risk the most whereas Risk [FRS] and Risk [ACC/AHA] have 
intermediate accuracy. The study findings suggest that Risk [JBS] may be suited for 
Indians 
26
. 
 
13. Holly C. Gooding et al did a study on cardiovascular risk assessment and cholesterol 
management in adolescents. They revealed that the major risk for cardiovascular 
disease was smoking, hypertension, hypercholesterolemia, diabetes and obesity. They 
concluded that risk assessment was very important for adolescent health 
27
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14. Mona Razavian et al conducted a study on cardiovascular risk management in chronic 
kidney disease in general practice (the AusHEART study- Australian Hypertension 
and Absolute Risk Study. Among a total of 4966 patients with kidney function test 
data, 1845 (37%) had abnormal kidney function. The study concluded that among 
CKD patients not prescribed blood pressure- lowering agents or lipid-lowering agents, 
treatment was indicated as per relevant guidelines in 51 and 46%, respectively. For 
CKD patients who were already prescribed blood pressure-lowering and lipid-
lowering agents, 61 and 50%, respectively, did not meet the treatment targets 
recommended by the relevant guidelines
28
. 
 
15. D S Prasad et al did a review about the association of smoking and cardiovascular 
health. They had concluded that tobacco use in India is complex and the burden was 
high and also it contributes to the pathogenesis of CVD. It also suggested that tobacco 
control is the most cost effective preventable cause of CV mortality and morbidity 
29
. 
 
16. Sonal Parikh et al conducted a study on assessment of cardiovascular disease risk by 
using Framingham risk equation among the residence of Ahmedabad city. The study 
reported that the risk was higher in males especially in unskilled workers and was due 
to high use of tobacco and other executive group it was because of disease conditions 
like diabetes and obesity 
30
. 
 
17. Z.Hambali et al conducted a study on oxidative stress and its association with 
cardiovascular disease in chronic renal failure patients. This study evaluated 
biomarkers of oxidative stress, NOx (total NO2 and NO3), and superoxide dismutase 
(SOD) enzyme in normal and CRF patients and correlated their association with 
CVD. However, it was noted that the levels of these biomarkers of oxidative stress 
were significantly lower in CRF patients with CVD compared with CRF patients 
without CVD. Therefore, these oxidative stress markers maybe contributing factors in 
the pathogenesis of CVD in patients with CRF
31
 
 
18. Sigrun Halvorsen et al studied the aspirin therapy in primary cardiovascular disease 
prevention. In which thrombosis place an important role in acute cardiovascular 
disease and has resulted in a large number of clinical trials on the effectiveness of 
antithrombotic drugs in cardiovascular disease prevention. Thus the study revealed 
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that aspirin is the primary prevention of CVD in both sexes at a risk level of 
cardiovascular events 
32
. 
 
19. Anping cai et al in their study on Lipoprotein associated phospholipase  
A2 [LP-PLA2] as a novel and promising bio-marker for CV risk assessment. They 
concluded that A2 [LP-PLA2] appears to be a valuable biomarker for discriminating 
patients CV risk.  And also could provide additive values of traditional risk factors in 
identifying a prone-rupture plaque 
33
. 
 
20. Emanuele Di Angelantonio et al conducted a study on chronic kidney disease and risk 
of major cardiovascular disease and non-vascular mortality: prospective population 
based cohort study. 16958 people aged 33-81 years without manifest vascular disease 
and with available information on stage of chronic kidney disease (defined by both 
estimated glomerular filtration rate and urinary protein) at study entry. The study 
concludes that in people without manifest vascular disease, even the earliest stages of 
chronic kidney disease are associated with excess risk of subsequent coronary heart 
disease. Assessment of chronic kidney disease in addition to conventional risk factors 
modestly improves prediction of risk for coronary heart disease. Further studies are 
needed to investigate associations between chronic kidney disease and non-vascular 
mortality from causes other than cancer
34
. 
 
21. Meg J. Jardine et al conducted a study on aspirin is beneficial in hypertensive patients 
with chronic kidney disease. They used HOT (Hypertension Optimal Treatment) 
study were they randomly assigned participants with diastolic hypertension to aspirin 
(75 mg) or placebo. Study treatment effects were calculated using univariate 
proportional hazards. From the study they concluded that aspirin therapy produces 
greater absolute reduction in major cardiovascular events and mortality in 
hypertensive patients with CKD than with normal kidney function
35
.  
 
22. Anthony J. Viera et al in their review on global risk of coronary heart disease: 
assessment and application reported that coronary heart disease is the most common 
cause of death in the United States. The conventional risk factor approach to primary 
prevention excludes many patients who could benefit from preventive therapies. It is 
based on an empiric equation that combines major risk factors, such as blood pressure 
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and cholesterol levels. When physicians know a patient’s global risk of coronary heart 
disease, they are more likely to prescribe risk-reducing therapies such as 
antihypertensives, statins, and aspirin. In addition, patients who know their risk level 
are more likely to initiate risk-reducing therapies. Many tools are available to estimate 
global risk, including several Web-based calculators. In the United States, tools based 
on the Framingham Heart Study are recommended
36
. 
 
23. Arvind Raghu et al did a study on implications of cardiovascular disease risk 
assessment using the WHO/ISH risk prediction charts in rural India. The study has 
demonstrated the differences in risk prediction of CV risks while using LI & HI 
models of WHO risk prediction charts 
37
. 
 
24. Sharon Anderson et al evaluated chronic kidney disease prediction, progression and 
outcomes in older adults. It is summarized in this article, to review what is known 
about chronic kidney disease, identify research gaps and resources available to 
address them, and identify priority areas for future research. Answers to emerging 
research questions will support the integration of geriatrics and nephrology and thus 
improve care for older patients at risk for chronic kidney disease
38
. 
 
25. Lisa M Miller et al conducted a clinical cross sectional study on cardioprotective 
medication use in hemodialysis patients. The study reports shows that cardiovascular 
disease is the leading cause of mortality in patients with renal failure, accounting for 
more than 50% of deaths in end-stage renal disease. Risk factor modification with the 
use of cardioprotective medications such as angiotensin converting enzyme inhibitors 
(ACEIs), beta-adrenergic antagonists (beta-blockers), acetylsalisylic acid (ASA) and 
3-hydroxy-3-methylglutaryl coenzyme A reductase inhibitors (statins) has been 
shown to reduce mortality in the general population. The study reports that many 
hemodialysis patients were not prescribed with cardioprotective medications. The 
results of the study suggest that secondary prevention strategies are not widely 
adhered to in dialysis patients. Each class of medications was prescribed to less than 
one-half of the entire cohort
39
. 
 
26. Jeffrey Brinker critically assessed cardiovascular risk in patients with chronic kidney 
disease. Studies have shown that even patients with mild kidney disease are greatly 
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increased risk of cardiovascular events. Patients with CKD should be assessed for 
coronary artery disease by traditional screening procedures as well as non tradional 
screening procedures such as C - reactive protein, homocysteine determinations. 
Reliable indicators for early kidney disease such as estimated creatinine clearance are 
perhaps underutilized in identifying patients who have increased cardiovascular risk 
as a result of renal insufficency
8
. 
 
27. Robert N. Foley et al studied chronic kidney disease and risk for cardiovascular 
disease, renal replacement, and death in the United States among medicare 
population. Knowledge of the excess risk posed by specific cardiovascular syndromes 
could help in the development of strategies to reduce premature mortality among 
patients with chronic kidney disease (CKD).On a relative basis, patients with CKD 
were at a much greater risk for the least frequent study outcome, renal replacement 
therapy. On an absolute basis, however, the high death rates of patients with CKD 
may reflect accelerated rates of atherosclerotic vascular disease and congestive heart 
failure
9
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4. OBJECTIVES OF THE STUDY 
 
The study entitled “Assessment and Prevention of risk for development of 
Cardiovascular diseases in Geriatric population with Chronic kidney disease” was 
aimed to achieve the following objectives: 
1. To assess the next 10 year  risk for  cardiovascular events in patients with chronic 
kidney disease using QRISK calculator, Framingham’s risk score and WHO 
charts. 
2. To compare the risks obtained from three scales. 
3. To provide prevention strategy for the patients with chronic kidney disease for 
their cardiovascular risk. 
4. To assess the prescription patterns for patients with chronic kidney disease. 
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5. PLAN OF THE STUDY 
The study entitled “Assessment and Prevention of risk for development of 
cardiovascular diseases in geriatric population with chronic kidney disease” was planned 
and carried out as given below: 
Phase 1 :- (December 2015 to January 2016) 
 Literature survey to identify the scope of the work 
 Submission of protocol and obtaining consent from hospital authority. 
 Designing of: 
 Data entry format 
 Patient information and consent form 
 Inclusion and exclusion criteria for data collection. 
 
Phase 2 : - (February to July 2016) 
 Data collection through standard data entry format in ward rounds. 
 Literature survey (continued) 
 Data analysis. 
Phase 3:- (August 2016) 
 Literature survey (continued) 
 Application of statistical tool on the obtained data. 
 Preparation and submission of reports. 
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6. METHODOLOGY 
Study Site 
The study was conducted at a private tertiary care hospital at Coimbatore. It is a 750 
bedded multi-specialty institution, one of the largest hospitals at Coimbatore. The hospital is 
unique and people from all over the country come and avail its facilities. The various 
specialties include General Medicine, Obstetrics and Gynecology, Pediatrics and Neonatal, 
Neurosciences, Anesthesiology, Orthopedics, Radiology, Nephrology, Pulmonology and 
Critical Care, Cardiology and Cardiothoracic surgery, Microbiology, Pathology and 
Hematology, Laparoscopic surgery, ENT, Dental and Maxillofacial surgery, Neurology, 
Ophthalmology, Physical Medicine and Rehabilitation, Diabetology, Surgical Gastro 
Enterology, Oncology. The hospital is also equipped with the modern diagnostic facilities 
like CT scan, MRI scan, PET scan, Ultra Sound Sonography, Digital Subtraction 
Angiography, ECG, Treadmill, Colour Doppler etc. The hospital also has twelve hi-tech 
operation theaters, Intensive Care Unit, Intensive Cardiac Care Unit, Intensive Pulmonary 
Care Unit, Catheterization, Balloon Valvuloplasty, Coronary stenting, Kidney transplantation 
unit with Haemodialysis machines and an assisted Reproductive Technology Centre. 24 hrs 
microbiological, blood bank, pathological services, round the clock causality and pharmacy 
services etc 
 
Department selected for study in the hospital 
The study was conducted in the department of Nephrology and general medicine. The 
reason for the selection of this department was that the pilot study revealed more scope for 
the study in the department of Nephrology. The  prevalence of chronic kidney disease were 
found to be more and the department of pharmacy practice provides service to the above 
department and a good co-operation from medical team added up as a reason for selecting the 
department for conducting the present study. The study was conducted with expert guidance 
of the Clinical Pharmacy Professionals and Physician from nephrology department.  
Consent from the hospital authorities 
It is mandatory that every project work carried out in the hospital by the  
M. Pharmacy (pharmacy practice) student has to be approved by the Institutional Ethical 
Committee of hospital. A protocol of the study which includes the objectives, methodology, 
and probable outcomes was prepared and submitted to the Institutional Ethical Committee of 
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the study hospital. The approval from the committee was procured through the letter 
[SRH/EC.5-7/2016-17 dated 26
TH
 February 2016] and the same was given in Annexure 
No.1for reference. The study was conducted with the expert guidance of senior and junior 
physicians of the departments selected. The author was permitted to utilize the hospital 
facilities to make a follow up of the cases, in the selected departments. All the health care 
professionals of the study site were well informed through Dean’s official circular. 
Literature survey  
Literature survey was done in order to collect the supporting evidence for the study 
proposed and this has been continued throughout the study period to update the knowledge 
about the topic and other related areas.  The necessary information from the literatures were 
collected and well documented. The literatures supporting the study were gathered from 
various sources such as: 
 Journal of the American society of nephrology 
 British Medical Journal 
 American heart association journals 
 Canadian journal of cardiology 
 Journal of the American College of Cardiology 
 Nephrology Dialysis Transplantion 
 Lancet global Health 
 American Academy of Family Physicians 
 International Education & Research Journal 
 Internship emergency medicine 
 Kidney international journal 
 Indian journal of nephrology 
 
IOWA Drug Information Services (IDIS), a database released by the College of  
Pharmacy, University of IOWA, Micromedex, Medscape, Pub med, Science direct and other 
databases were also been widely used. 
 
The following were some of the textbooks used for references were, 
1.Joseph. T. Dipiro, Pharmacotherapy-A pathological Approach by 7
th
 edition  (2008); pg. 
no.619-624. 
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2.Roger Walker and Cate Whittlesea; Clinical Pharmacy and Therapeutics; 5
th
 edition 
(2012); pg.no.213-220,132-140. 
3.K.D. Tripathi. Essentials of medical pharmacology; 6
th
 edition; pg. no.  
 667-808. 
4.Mohsen Ziai M.D; Pediatrics; 3
rd
 edition; pg.no. 1-5. 
 
Design of patient informationform 
 
A patient information form has been prepared, to inform the care givers of patients 
about the purpose, necessity of the study and assuring them that the confidentiality will be 
strictly maintained and this is for only the betterment of patient’s health. The format includes 
the details like Department address, name and signature of the investigator and supervisor, 
date, place and details of the study. The model of the patient information form was given in 
the Annexure No.: 2 for reference. 
 
Design of patient consent form 
A patient consent form has also been prepared to obtain written consent from all the 
patient or bystander and will be included in the study. They will be informed about the study 
using patient consent form. The format contains details like address, date, place, provision for 
signature of the patient or bystander, investigator and supervisor. The same was given in the 
Annexure No.: 3 for reference. 
 
DESIGN OF DATA ENTRY FORM 
 A separate data entry form for incorporating patient details were designed and the 
format contains provision to enter the details such as name, age, sex, height, weight, IP. No, 
date of admission, date of discharge, vital signs, reason for admission, past medical history, 
past medication history, and any predisposing factors. Provision was given in the format for 
entry of details like blood counts, liver function test, renal function test, pulmonary function 
test, electrolytes, urine examination, diagnosis, drug chart, and drug interaction chart and 
dose and any interventions. The model of the patient Data entry form was given in the 
Annexure No.: 4 for reference. 
 
Inclusion criteria: All in-patients of age above 64 years of either sex admitted into the study 
site during the study period, who have been diagnosed to have chronic kidney disease with 
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serum creatinine measurement and are willing to participate will be included in the study. 
 
 Exclusion criteria: Patients, younger than 65 years, patients with no serum creatinine 
measurement or with insufficient data, critically ill, out-patients and who were not willing to 
participate were be excluded from the study. 
 
Data collection 
Data were collected during a regular ward round participation in the department of 
Nephrology and general medicine. Patients who had satisfied the inclusion criteria were 
included. Patient or care givers were informed about the study and their written consent was 
obtained from them, using appropriate forms. Data collection form was used to obtain 
information on demographics of patient (e.g. Patient name, age, gender, height, weight, data 
of admission and date of discharge), presenting complaints, provisional/ confirmed diagnosis, 
drug therapy given (with brand name and generic name of each drug, dose, duration and route 
of therapy) and laboratory test reports.  
 
Data analysis 
 Prospective observational cross sectional study was used to assess cardiovascular risk 
for next 10 years in patients with chronic kidney diseases. Data concerning to patients’ socio-
demographic and economic profiles, will be collected through interviews from patients and 
consultation of medical files to obtain clinical, laboratory and anthropometric data. The 
collected data was analysed using Microsoft Excel spreadsheet. Frequency tables were used 
for the categorical variables (gender, age, diabetes and hypertension) and descriptive statistics 
(average, standard deviation) for the continuous variables. The Chi-square test was used for 
the analysis of association among the following variables: risk factors, gender, and age at a 
level of significance of p<0.05 was adopted. 
 
The Framingham Risk Score
25
 was be used to assess cardiovascular risk. The same 
was given in the Annexure No.:5 for reference. The total score takes into account the 
following variables: gender, age, smoking, diabetes mellitus, high-density lipoprotein, total 
cholesterol, systolic blood pressure and diastolic blood pressure. The score obtained 
corresponds to the likelihood of cardiovascular diseases occurring in the next ten years, 
expressed as a percentage. Hence, the individuals were classified in the following categories: 
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low risk, which refers to a probability lower than 10% of cardiovascular events occurring in 
ten years; average risk, between 10% and 20%; and high risk, greater than 20%
7
. 
 
The results were analysed by means ofQRISK
®
2  a well-established cardiovascular 
disease (CVD) risk score, which is designed to identify people at high risk of developing 
CVD who need to be recalled and assessed in more detail to reduce their risk of developing 
CVD. The QRISK
®
2 score estimates the risk of a person developing CVD over the next 10 
years.QRISK
®
2 has been specifically developed by doctors and academics for use in the 
UK.The original research underpinning QRISK
®
 was published in July 2007 in the British 
Medical Journal and in January 2008 in Heart journal
40
. The original research underpinning 
version 2 of QRISK
®
 (QRISK
®
2) has been published in the British Medical Journal in June 
2008
40
.The research was done using the QResearch anonymised medical research database 
which consists of the electronic health records of over 10 million patients registered with 550 
general practices using the EMIS clinical computer system of whom 2 million contributed to 
the Q Research database.  
 
The results were also analysed through WHO charts. These charts indicate 10-year 
risk of a fatal or non-fatal major cardiovascular event (myocardial infarction or stroke), 
according to age, sex, blood pressure, smoking status, total blood cholesterol and presence or 
absence of diabetes mellitus for 14 WHO epidemiological sub-regions. The charts provide 
approximate estimates of cardiovascular disease (CVD) risk in people who do not have 
established coronary heart disease, stroke or other atherosclerotic disease. The WHO charts 
was given in Annexure No.6 for reference. They are useful as tools to help identify those at 
high cardiovascular risk, and to motivate patients, particularly to change behaviour and when 
appropriate to take antihypertensive, lipid-lowering drugs and aspirin. 
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7. RESULTS 
 The study entitled “Assessment and Prevention of risk for development of 
cardiovascular diseases in geriatric population with chronic kidney disease” has the 
following results. Data were collected from the study population of 102 geriatric patients who 
had fulfilled the inclusion criteria. The obtained data were analyzed and the results were 
given in the following sections. 
Prevalence of CKD: 
The study site had 1667 patients admitted during the study period. There were 102 
patients included in the study as they matched the inclusion and exclusion criteria of the 
study. Hence the prevalence of chronic kidney disease among the geriatrics was 6.1%.  The 
prevalence details are given below.Tab.No.5 
Tab.No.5:- Prevalence of CKD patients 
S.No. Description Number of Patients % Patients 
1. Patients who were not 
included in the Study 
1565 93.9% 
2 Patients included in the study 102 6.1% 
 
Gender distribution 
The study results revealed that a predominant male population of 57.84% was observed 
among the study population and the same was depicted in Fig. No: 5. 
Age Distribution 
The study population was categorized into young or new elderly (65-74), old elderly 
(75-84), oldest old (>84).Age distribution of the study population was analyzed and it was 
found that 85.29% were in the age group 65-74 years in which males were 89.83% and 
females 79.06%. The details of the age distribution of the study population were given in 
Tab. No.6. 
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Fig. No. 5: - Gender distribution (n=102) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Tab. No.6: - Age categorisation of study population (n=102) 
 
  
Age group 
Percentage 
Male (No.) 
(n=59) 
Percentage 
Female (No.) 
(n=43) 
Over all 
percentage(No.)
(n=102) 
65 to 74years 
(New elderly) 
89.83(53) 79.06(34) 85.29(87) 
75-84 years 
(Old elderly) 
7.54(4) 18.60(8) 11.76(12) 
> 84 years 
(oldest old) 
3.77(2) 2.32(1) 2.94(3) 
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Body Mass Index (BMI) 
The Body Mass Index of the study population was calculated by using weight and 
height of the patient. The BMI were calculated using the following formula: 
BMI = weight in kilograms / height in meters
2
 
 
As the BMI is a modifying risk factor for an individual to have cardiovascular risk 
and thus the classification becomes very important. Results revealed that 20.54% of the study 
population were having greater BMI value than normal and also at high risk category for 
getting cardiovascular disease in future.  It also reveals that 79.40% were very well normal 
and do not have the risk. The details were given in Tab.No.7. 
Tab. No.7: - Body mass index (n=102) 
Category Value 
Percentage  
Males(No.) 
(n=59) 
Percentage  
Females(No.) 
(n=43) 
Over all  
percentage(No.) 
(n=102) 
Severe thinness <16     ---   ---- 
 
Moderate thinness 16 to17   ----   ----   ---- 
Mild thinness 17 to 18.5  16.94 (10)  11.62(5) 14.70(15) 
Normal 18.5 to 25 62.71(37) 67.44(29) 64.70(66) 
Over Weight 25 to 30 16.94(10) 18.60(8) 17.64(18) 
Obese class I 30 to 35 1.69(1)   ---- 0.98(1) 
Obese class II 35 to 40 1.69(1) 2.32(1) 1.92(2) 
 
Length of Stay 
 Length of stay of study population in hospital were analyzed and the results were 
given in Tab. No.8.It was found that 55.87% of study population had atleast for minimum6 
days in the hospital. This analysis had given an insight of the cost incurred for the treatment 
which would be generally high if the number of days stay is going to be more. The minimum 
number of days of hospital stay for the study population was found to be 2 days and 
maximum 15 days. The average number of days of hospital stay was found to be5.470 
± 2.639 days 
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Tab. No.8:- Length of stay (n=102) 
Days Percentage(No.) 
<3 13.72(14) 
3 to 5 30.39(31) 
6 to 8 32.35(33) 
9 to 10 15.68(16) 
>10 7.84(8) 
 
Reasons for Admission 
 The analysis of reasons for admission to the study site had revealed that certain 
complaints like difficulty in breathing, vomiting, swelling of limbs, decreased urine output 
etc., were found to be very common. The details of the complaints were given in Tab. No.9. 
Past Medical History 
The past medical history of the study population was also analyzed and the data were 
available with only few patients. The details were given below Tab. No.10 Results revealed 
that diabetes mellitus, chronic renal failure and hypertension were very prevalent among the 
study population. 
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Tab. No.9:- Reasons for admission (n=102) 
S. No. Complaints Percentage(No.) 
1 Difficulty in breathing 32.35(33) 
2 vomiting 16.66(17) 
3 Swelling of limb 15.68(16) 
4 Decreased urine output 14.70(15) 
5 Fever  12.74(13) 
6 Decreased appetite 7.84(8) 
7 Nausea  6.86(7) 
8 Loose stools 6.86(7) 
9 Fatigue  6.86(7) 
10 Elevated renal parameters 5.88(6) 
11 Back pain 5.88(6) 
12 Cough  4.90(5) 
13 Slurry of speech 3.92(4) 
14 Ulcer  3.92(4) 
15 Headache  3.92(4) 
16 Knee pain 2.94(3) 
17 Leg swelling 1.96(2) 
18 Diarrohea  1.96(2) 
19 Chest pain 1.96(2) 
20 Giddiness  1.96(2) 
21 Weight loss 0.98(1) 
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Tab.No.10:- Past medical history 
S. No. Diseases  Percentage(No.) 
1 Diabetes mellitus 50(51) 
2 
Chronic renal 
failure 32.35(33) 
3 Hypertension  28.43(29) 
4 Asthma  5.88(6) 
5 Hypothyrodism  3.92(4) 
6 COPD 1.96(2) 
7 Parkinson’s disease 0.98(1) 
8 Liver Cirrhosis  0.98(1) 
 
Past Medication History 
 
The details about the past medication history of study population was also done and 
details were available with only few and given below Tab.No.11. 
 
Tab.No.11:-Past medication history 
 
S. No. Drugs  Percentage(No.) 
1 Insulin  13.72(14) 
2 Amlodipine  12.74(13) 
3 clinidipine 9.80(10) 
4 Glimipride  8.82(9) 
5 Telmisartan  7.84(8) 
6 Atorvastatin  4.90(5) 
 
Family History 
The analysis of family history of having any of the disease conditions becomes more 
important as this is one of the non –modifying risk factor of having cardiovascular disease 
was family history. The details of having of such analysis are given in Tab.No.12 
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Tab.No.12:-Details of family history 
Sl. No. Disease  Percentage(No.) 
1 Diabetes mellitus  32.35(33) 
2 SHT 20.5(21) 
3 CRF 1.96(2) 
 
 
Social History 
The individual habit reluctant to taking of alcohol and tobacco becomes an important 
risk factor for most of clinical condition in this regard 79.4%of study population didn’t have 
the risk of having cardiovascular risk because they do not have the habit of smoking or 
drinking of alcohol. The details were given below in the Tab.No.13 
Tab.No.13:- Social history 
Sl. No. Social habits Percentage(No.) 
1 None  79.4(81) 
2 Alcoholic  1.96(2) 
3 Tobacco 18.62(19) 
 
Laboratory Investigations 
 The laboratory investigations for the study population were given below 
Tab. No: 14. The result had revealed that electrolytes serum creatinine, urea, and GFR were 
commonly assessed to most of the study population as it has included CRF patients. 
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Tab. No: 14: - Laboratory investigation (n=102) 
 
Sl. No. Investigations Percentage(No.) 
1 Electrolytes 100(102) 
2 Serum creatinine 100(102) 
3 Urea 97(99) 
4 GFR 96.07(98) 
5 Hemoglobin 88.23(90) 
6 WBC 86.27(88) 
7 CNS 76.47(78) 
8 CVS 73.52(75) 
9 Platelet 63.72(65) 
10 Temperature 58.82(60) 
11 Blood glucose 49.01(50) 
12 Liver function test 41.76(42) 
13 RBC 38.23(39) 
14 Lipid profile 14.70(15) 
15 ESR 9.80(10) 
16 Echo 1.96(2) 
17 endoscopy 1.96(2) 
18 epithelial 0.98(1) 
 
Diagnosis 
The provisional diagnosis of the study population was also analyzed and the common 
diagnosis was found to be systemic hypertension, diabetes mellitus, chronic renal failure, etc. 
The details were given below Tab. No.15. Results revealed that the modifying variable risk 
factors other than CRF, systemic hypertension, diabetes mellitus and renal failure were also 
very prevalent among the study population. In general anemia will be more common in CRF 
patient which is also evident in the study population. 
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Tab. No.15: - Diagnosis (n=102) 
 
S. No. Diseases Percentage(No.) 
1 CRF & other related disease 100(102) 
2 Diabetes mellitus 38.23(39) 
3 Hypertension  22.54(23) 
4 Anaemia 18.62(19) 
5 Bronchial asthma 5.88(6) 
6 Hypothyroidism  4.90(5) 
7 UTI 2.94(3) 
8 Renal stone disease 2.94(3) 
9 Hyperkalemia  2.94(3) 
10 COPD 1.96(2) 
11 Acute pulmonary edema 1.96(2) 
12 Renal biopsy 1.96(2) 
13 Global hyperkinesia 1.96(2) 
14 Liver cirrohsis 1.96(2) 
15 Acute gastroenteritis 1.96(2) 
16 Alcohol hepatitis 1.96(2) 
17 Seizure disorder 0.98(1) 
18 Parkinson’s disease 0.98(1) 
19 Glomerular nephritis 0.98(1) 
20 Migraine  0.98(1) 
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Drug Categories 
 
The drugs used in study population were analyzed and the list of drugs prescribed was 
shown in Tab. No: 16. Analysis revealed that majority of the study population has received 
anti-hypertensive and antibiotics and proton pump inhibitors. And almost majority of 
population has received one or more vitamin supplements. The average was found to be 
8.009±2.852.The maximum number of drugs given to patient is 14 and minimum is 3. 
 
Tab. No: 16A – Drug categories (n=102) 
S.No. 
 
Drugs category (%) 
n=817 
Name of the drug 
 
Percentage(No.) 
n=102 
1 
Vitamins and 
mineral(30.50) 
calcitrol 53.9(55) 
Calcium acetate 47.05(48) 
Folic acid 42.1(43) 
Vitamin supplements 30.3(31) 
alfacalcidol 16.6(17) 
Alpha glutaanalogue 13.7(14) 
Methylcobalamin  9.8(10) 
iron 9.8(10) 
calcium 8.82(9) 
Multivitamins 5.8(6) 
Pregabalin 3.9(4) 
Biotin  0.98(1) 
2 
Anti-hypertensives 
(11.31) 
Clinidipine  37.2(38) 
Metoprolol  10.7(11) 
Nebivolol 10.7(11) 
Prazocin  8.82(9) 
Amlodipine  5.8(6) 
Atenolol  3.92(4) 
Moxonidine  3.92(4) 
Losartan  3.92(4) 
Clonidine  1.92(2) 
Naftopidil  1.92(2) 
Alfazocin  0.98(1) 
3 
 Antibiotics (9.59) 
Piperacillin 
sodium+tazobactum 19.6(20) 
Pre -probiotics 13.7(14) 
Cefalosporins 12.7(13) 
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Penicillin 7.8(8) 
Amoxicillin+clavulanic acid 7.8(8) 
Cefixime + sulbactam 2.9(3) 
Ornidazole 2.9(3) 
Imepenam+cilastin 1.9(2) 
Ofloxacin 1.9(2) 
Macrolides 1.9(2) 
Garamycin 0.98(1) 
Ceftriazone 0.98(1) 
Levofloxacin 0.98(1) 
4 
Proton pumb inhibitor 
(9.10) 
Pantoprazole  67.6(69) 
esomeprazole 4.9(5) 
5 Anti anginal drugs(6.64) 
Atorvastatin  23.5(24) 
Isosorbide mononitrate  11.7(12) 
Nicorandil  4.9(5) 
Levocarnitine  3.92(4) 
Amlodarone  2.92(3) 
Trimetazidine  2.9(3) 
Digoxin  1.92(2) 
Rosuvastatin  0.98(1) 
6 Diuretics (3.19) 
Torsemide  21.5(22) 
Furosemide  1.92(2) 
Spirolactone  1.92(2) 
7 
Anti –
hyperurisemia(3.19) Febuxostat  25.4(26) 
 
Tab. No: 16B – Drug categories (n=102) 
Sl.No. 
 
Drugs category (%) 
n=817 
Name of the drug 
 
Percentage(No.) 
n=102 
1 Anti –emetics (2.95) 
Ramosetron  18.62(19) 
Ondansetron  3.9(4) 
Metoclopramide  0.98(1) 
2 
Anticoagulants 
(2.33) 
clopidogrel 8.8(9) 
Asprin+clopidogrel   7.8(8) 
warfarin 1.9(2) 
3 Analgesics (2.21) Paracetamol  17.6(18) 
4 Antidotes  (2.09) 
sevalmer 10.7(11) 
Acetyl cysteine 5.7(6) 
5 
Hypoglycemic agents  
(2.09) 
Insulin  11.7(12) 
Glimipride  0.9(1) 
Linagliptin  0.9(1) 
Sitagliptin  0.9(1) 
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6 Hormones (2.09) 
Methyl prednisolone 8.82(9) 
Levothyroxine  3.9(4) 
Erythropoietin  1.92(2) 
7 Antiepileptics (2.09) 
Clobasam  4.9(5) 
Mecobalamine  2.9(3) 
Piracetam  2.92(3) 
Flunarazin  1.92(2) 
Citicoline  0.98(1) 
Diazebam  0.98(1) 
8 Antacids (1.59) 
Sodium bicarbonate  6.8(7) 
Pantoprazole+domperidone 3.92(4) 
Famotidine  1.92(2) 
9 Anti-diarroheals (1.23) 
Vibact  8.8(9) 
Racecodril  0.92(1) 
10 Anti-asthmatics (1.10) 
Etophylline+theophylline  5.8(6) 
Acebrophylline  2.9(3) 
11 
Anti-inflammatory 
agents(1.10) 
Tramadol  3.9(4) 
Chymotrypsin  2.9(3) 
 
Tab. No: 16 C – Drug categories (n=102) 
Sl.No. 
 
Drugs category (%) 
n=817 
Name of the drug 
 
Percentage(No.) 
n=102 
1 Hepatic protectors (0.98) 
Ursodeoxycholic 
acid 7.8(8) 
2 Anti vertigo(0.98) 
Betahistine  5.8(6) 
meclozine 1.9(2) 
3 Anxiolytics (0.86) 
Hydroxyzine  2.9(3) 
Alprazolam  2.92(3) 
Clonotril  0.96(1) 
4 Haemotropic (0.73) 
Darbepoetin alpha 4.9(5) 
Transeamic acid 0.9(1) 
5 Anti tussives (0.49) 
bromohexine 1.9(2) 
levocloparasitine 1.9(2) 
6 Immunosupprasants (0.49) 
Tarcolimus  1.9(2) 
Azathioprine  1.9(2) 
7 Anti-fungal (0.49) Fluconazole  3.9(4) 
8 Anti-malarials  (0.36) HCQS 2.92(3) 
9 Appetite enhancer (0.36) Elixir neogardine  2.9(3) 
10 Laxatives (0.24) Liquid paraffin  1.92(2) 
11 Sedatives (0.12) Zolpedem  0.92(1) 
12 Anti tuberculosis (0.12) Ethambutol  0.92(1) 
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Route of Administration 
Route of administration of the prescribed drugs to the study population was analyzed. 
The detail of route administration was given in Tab. No. 17&17 A. The analysis had revealed 
that about 83.33% of patients had received injectables prescribed and that accumulated to 
about 22.64% of total drugs that were given as injection to the study population. 
Tab. No.17: - Route of adminstration of drugs (n=102) 
Route Percentage(No.) 
Oral 100(102) 
Injectable 83.33(85) 
 
Tab. No. 17A: - Route of adminstration of drugs (n=817) 
Route Percentage(No.) 
No . of Oral drugs 77.35(632) 
No. of Injectables 22.64(185) 
 
STAGES OF KIDNEY DISEASE 
The various stages of kidney disease was analysed and found that only 10% of 
population belongs to stage I and II and rest where above stage III. The results were given in 
Tab.No.18. 
Tab.No.18:- Stages of kidney disease 
 
 
 
 
 
 
Stages 
Percentage 
Male (No.) 
(n=59) 
Percentage 
Female (No.) 
(n=43) 
Over all 
percentage(No.)
(n=102) 
Stage I 1.69(1) 4.65(2) 2.94(3) 
Stage II 6.77(4) 11.62(5) 8.82(9) 
Stage III 52.54(31) 41.86(18) 48.03(49) 
Stage IV 22.03(13) 23.25(10) 22.54(23) 
Stage V 16.94(10) 18.60(8) 17.64(18) 
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The prevalence of haemodialysis patient among study population was analysed. It was 
found 30.29% of them had undergone haemodialysis and majority of the population was non-
hemodialysis patient. The patient undergoing hemodialysis were belong to stage IV and  
stage V. 
CARDIOVASCULAR RISK ASSESSMENT 
QRISK Scale Risk Assessment 
The 10 year risk was assessed through QRISK calculator. Results had revealed that 
29.41% of the study population were been categorised in the risk level of ≥40% in which 
42.37% were males and 11.6% were females. The detail are given below Tab no.19& Fig 
no.6 
Tab. No. 19:– Q-RISK Assessment (n=102) 
 
Risk Level 
Percentage of 
Males(No.) 
(n=59) 
Percentage of 
Females(No.) 
(n=43) 
Over all  
Percentage(No.) 
(n=102) 
<10% - - - 
10 to 20% 3.38(2) 16.2(7) 8.82(9) 
21 to 30% 23.72(14) 39.5(17) 30.19(31) 
31 to 40% 30.50(18) 32.5(14) 31.3(32) 
≥40% 42.37(25) 11.6(5) 29.41(30) 
 
Fig.No.6:- Q-RISK assessment (n=102) 
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Framinghams Risk Assessment 
The Framingham Risk Score is a gender-specific algorithm used to estimate the 10 
year cardiovascular risk of an individual. The Framingham Risk Score was first developed 
based on data obtained from the Framingham Heart Study, to estimate the 10-year risk of 
developing coronary heart disease. The datas were analysed using Framingham risk 
calculator and it was found that 24.50% of population were at high risk in which males were 
37.28% and females were 9.93%.the details were given below Tab No.20 and Fig.No.7. 
Tab. No.20:- Framinghams Risk Assessment 
Risk Level 
Percentage of 
Males(No.) 
(n=59) 
Percentage of 
Females(No.) 
(n=43) 
Over all  
Percentage(No.) 
(n=102) 
<10% - - - 
10 to 20% 1.69(1) 18.60(8) 8.82(9) 
21 to 30% 25.42(15) 37.20(16) 31.3(32) 
31 to 40% 35.59(21) 37.20(16) 35.29(36) 
≥40% 37.28(22) 9.93(4) 24.50(25) 
 
Fig No.7:- Framinghams risk assessment 
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WHO Scale Risk Assessment 
The cardiovascular risk assessments of the study population obtained by using WHO 
scale were given in Tab. No.21 and Fig. No: 8. Result had revealed that 28.43% of the study 
population were been categorised in the risk level of ≥40% in which 33.89% were males and 
4.65% were females. An overall 4.90%  study population only were having risk of level less 
than 10%.  
Tab. No. 21:- WHO Scale Risk Assessment 
Risk level 
Percentage of 
Males(No.) 
(n=59) 
Percentage of 
Females(No.) 
(n=43) 
Over all  
Percentage(No.) 
(n=102) 
<10% 5.08(3) 4.65(2) 4.90(5) 
10 to 20% 10.16(6) 30.23(13) 18.62(19) 
21 to 30% 28.81(17) 37.20(16) 30.39(31) 
31 to 40% 12.74(13) 23.25(10) 22.54(23) 
≥40% 37.28(22) 4.65(2) 23.52(24) 
 
Fig. No.8:- WHO scale risk assessment 
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Comparison of the Risk Scales 
Comparison of the risk assessment by different scales had revealed that WHO scale 
using chart values has categorised 4.9% of the study population into very low or no risk 
category where the other scales didn’t categorise anyone in that category but in the very high 
risk category all the three scales were able to categorise more or less similar difference in the 
result. The use of QRISK calculator was reported to be more accurate and use WHO charts. 
The result also revealed a similar number between QRISK and Framingham’s in all the 
categories of risk level but WHO scale differs
38
.The details of comparison is given below 
Tab.No.22 
 
Tab.No.22:- Comparison of the Risk Scales 
 
 
Risk level Risk score QRISK 
Framingham’s 
score 
WHO scale 
No risk <10% - - 4.90(5) 
Low risk 10 to 20% 8.82(9) 8.82(9) 18.62(19) 
Moderate risk 21 to 30% 30.19(31) 31.3(32) 30.39(31) 
Light risk 31 to 40% 31.3(32) 35.29(36) 22.54(23) 
Very high risk ≥40% 29.41(30) 24.50(25) 23.52(24) 
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Drug Related Problems 
 
The analysis of drug related problems in the prescription given to the study population 
had revealed the following DRP’s. The details were shown below in Tab.No. 23. 
Tab.no.23:- Drug Related Problems 
Sl.No. 
Drug Related 
Problems 
Drugs Problems Interventions 
1 Dosage 
adjustment 
Inj.tazar 
(pipercillin+tazoba
ctum 
4.5gm is given  bd 2.25 gm is the 
recommended dose for 
renal impairment 
patients 
Tab.aldactone 
(spirolactone) 
50mg 25 mg orally once daily 
2 Drugs 
prescribed 
without 
indication 
Inj. Vitamin K It is prescribed for 
coagulation 
It can be avoided. 
Tab.Abphylline sr The drug was prescribed 
for asthma 
It can be avoided. 
Tab.storvas The drug was prescribed 
for hypertension 
It can be avoided. 
3 No drugs for 
indication 
Bronchial asthma Drugs  was not prescribed Tab. Deriphylline 
100mg bd can be given. 
COPD Drugs was not prescribed Tab. Deriphylline 
100mg bd can be given. 
Hyperuresemia Drugs not prescribed Tab.Febuxostat40 mg 
bd can be given 
Hypothyroidism  Drugs not prescribed Tablet thyronorm 
50mcg can be given 
4 Therapeutic 
duplication 
Inj.pan and 
tab.pantocid  was 
precribed 
Affects therapeutic 
efficacy 
Inj.pan may  be avoided 
Inj.pan and 
tab.sompraz d 
Synergestic effect Inj .pan may be 
aavoided 
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Drug Interactions 
 The analysis of drug-drug interaction prevailing in the prescriptions of study 
population had revealed that 44.11% of prescriptions were having one or more interaction 
and rest 55.88% didn’t have even one drug-drug interaction. There were about 21 drug-drug 
interactions prevailing in the prescriptions of study population which account of a drug – 
drug interaction. The average was found to be 0.6568±0.969.The details of the number of 
interactions were given in Tab. No.24. 
Tab. No.24: - Drug interaction Categorisation (n=102) 
Drug interactions Percentage(No.) 
No interaction 55.88(57) 
One interaction 21.56(22) 
Two  interaction 12.74(13) 
Three  interaction 4.90 (5) 
 
The Tab. No.24A: - 24C will be giving the details of drug-drug interactions prevailing in the 
prescription.  
Tab. No. 24A: - Major Drug Interactions 
Precipitant 
Drug 
Interacting 
drug(No.) 
Effect Inference 
Warfarin Piperacillin + 
tazobactam (3) 
Increased risk of bleeding Monitoring of patients 
INR is recommended 
Torasemide (4) Increased warfarin concentration, 
decreased warfarin clearance, 
elevated INR 
Adjust warfarin dose 
Amlodipine Clopidogrel (2) Decreased anti-platelet effect, 
Increased risk of thrombotic 
events 
Monitor patient for loss of 
clopidogrel efficacy 
Azithromycin Fluconazole (3) Increased risk of  QT interval 
prolongation 
Monitor ECG 
Ondansetron (2) Increased risk of  QT interval 
prolongation 
Monitor ECG 
Calcium acetate Phenytoin (2) Decreased exposure phenytoin Consider separating the 
dose of oral phenytoin and 
antacids by several hours  
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Tab. No.24B: – Moderate Drug Interactions 
Precipitant 
Drug 
Interacting 
drug(No.) 
Effect Inference 
Warfarin Acetaminophen 
(3) 
Increased risk of bleeding Frequent monitoring of INR 
for several weeks when 
acetaminophen is added or 
discontinued 
Pantoprazole (4) Increased INR ratio and 
prothrombin time 
Warfarin dosage adjustments 
may be required 
Tramadol (4) Increased risk of bleeding and 
prothrombin time 
Monitor INR and adjust 
warfarin doses accordingly 
Iron Pantoprazole (4) Reduced bioavailability Monitor patient for iron 
efficacy if pantoprazole is 
being used concurrently 
Atorvastatin Clopidogrel (11) High platelet reactivity Discontinue statin 
Torasemide Clopidogrel (3) Increased torasemide toxicity Monitor torasemide toxicity 
Calcium acetate Levofloxacin (2) Decreased levofloxacin 
effectiveness 
Administer a different 
antibiotic or alternative 
therapy 
Clobazam Nebivolol (4) Increased nebivolol plasma 
concentration 
Dose reduction may be 
warranted for nebivolol 
Metoprolol Sitagliptin + 
metformin (3) 
Results in hypoglycemia Closely monitor for 
hypoglycaemia with 
concurrent use 
Clobazam Phenytoin (2) Increased risk of phenytoin 
toxicity 
Monitor for signs of 
phenytoin toxicity with 
combined therapy 
Levothyroxine Pantoprazole (3) Increased TSH levels Monitor TSH levels closely 
Adjust levothyroxine doses 
Torasemide Diclofenac (3) Decreased diuretic and 
antihypertensive efficacy 
Caution when NSAIDS and 
loop diuretics are co-
administered 
Calcium acetate Ofloxacin (1) Decreased ofloxacin 
effectiveness 
Concurrent administration of 
ofloxacin and aluminium, 
calcium, or magnesium 
containing products is not 
recommended 
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Tab. No.24 C: - Minor Drug Interactions 
 
 
STATATISTICAL ANALYSIS 
 
 The statistical analysis was done using SPSS software version 20. Chi square test had 
been used for the analysis.  The statistical analysis had revealed the following results were an 
attempt to correlate the gender and risk scores obtained by using all the three scales revealed 
that there is a significant (p <0.05)relationship between the risk score obtained and gender. 
Similarly, the risk scores were correlated with age of the study population which revealed a 
significant correlation.  
 
The modifiable risk factors including presence of Diabetes mellitus, was found to be 
significant whereas  the systemic hypertension and various stages of CKD didn’t show any 
significance. The details were given in Tab. No.25 -29 
 
  
Precipitant Drug 
Interacting 
Drug(No.) 
Effect Inference 
Calcium acetate Iron (2) Decreased iron 
effectiveness 
It is not recommended else 
iron should be taken one 
hour before. 
Calcium acetate Atenolol (2) Reduced effectiveness 
of atenolol 
Atenolol should be 
administered two hours or six 
hours after the 
aluminum,calcium,magnesiu
m containing product 
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Tab.No.25 A:- Chi square test risk scores Vs Gender 
 
RISK ASSESSMENT 
Gender Total p value 
Male, 
n(%) 
Female, 
n(%) 
n (%)  
Q-RISK 
ASSESSMENT 
<10 0 0 0 
0.052 
10-20 5(4.9) 9(8.8) 14(13.7) 
21-30 17(16.7) 13(12.7) 30(29.4) 
31-40 17(16.7) 13(12.7) 30(29.4) 
≥40 22(21.6) 6(5.9) 28(27.5) 
WHO SCALE 
RISK 
ASSESSMENT 
<10 1(0.9) 0 1(0.9) 
0.017 
10-20 9(8.8) 13(12.7) 22(21.6) 
21-30 15(14.7) 15(14.7) 30(29.4) 
31-40 11(10.8) 8(7.8) 19(18.7) 
≥40 25(24.7) 5(4.9) 30(29.4) 
FRAMINGHAMS 
RISK 
ASSESSMENTT 
<10 0 0 0 
0.007 
10-20 7(6.9) 9(8.8) 16(15.7) 
21-30 14(13.7) 13(12.7) 27(26.5) 
31-40 17(16.7) 16(15.7) 33(32.4) 
≥40 23(22.6) 3(2.9) 26(25.4) 
 
 
Tab.No.26:- Chi square test risk score Vs Age 
RISK ASSESSMENT 
Age Total 
p value <70, 
 n (%) 
70-80,  
n(%) 
>80,  
n(%) 
n (%) 
Q-RISK 
ASSESSMENT 
<10 0 0 0 0 
0.001 
10-20 13(12.7) 1(0.9) 0 14(13.7) 
21-30 21(20.6) 9(8.8) 0 30(29.4) 
31-40 18(17.7) 11(10.9) 1(0.9) 30(29.4) 
≥40 10(9.8) 11(10.9) 7(6.8) 28(27.5) 
WHO SCALE 
RISK 
ASSESSMENT 
<10 1(0.9) 0 0 1(0.9) 
0.161 
10-20 14(13.9) 7(6.8) 1(0.9) 22(21.6) 
21-30 21(20.8) 8(7.8) 1(0.9) 30(29.4) 
31-40 10(9.8) 9(8.9) 0 19(18.7) 
≥40 16(15.8) 8(7.8) 6(5.9) 30(29.4) 
FRAMINGHAMS 
RISK 
ASSESSMENTT 
<10 0 0 0 0 
0.216 
10-20 12(11.8) 4(3.9) 0 16(15.6) 
21-30 15(14.7) 11(10.9) 1(0.9) 27(26.5) 
31-40 21(20.6) 10(9.8) 2(1.9) 33(32.4) 
≥40 14(13.8) 7(6.8) 5(4.9) 26(25.5) 
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Tab.No.27:- Chi square test risk scores Vs Diabetes Mellitus 
RISK ASSESSMENT 
Diabetes mellitus Total 
p value Yes,  
n (%) 
No,  
n(%) 
n (%) 
Q-RISK 
ASSESSMENT 
<10 0 0 0 
0.007 
10-20 4(3.9) 10(9.8) 14(13.7) 
21-30 11(10.8) 19(18.6) 30(29.4) 
31-40 13(12.7) 17(16.7) 30(29.4) 
≥40 21(20.6) 7(6.9) 28(27.5) 
WHO SCALE 
RISK 
ASSESSMENT 
<10 0 1(0.9) 1(0.9) 
0.001 
10-20 4(3.8) 18(17.7) 22(21.6) 
21-30 12(11.8) 18(17.7) 30(29.4) 
31-40 11(10.9) 8(7.8) 19(18.7) 
≥40 22(21.6) 8(7.8) 30(29.4) 
FRAMINGHAMS 
RISK 
ASSESSMENTT 
<10 0 0 0 
0.001 
10-20 3(2.9) 13(12.7) 16(15.7) 
21-30 8(7.8) 19(18.6) 27(26.5) 
31-40 21(20.6) 12(11.8) 33(32.3) 
≥40 17(16.7) 9(8.9) 26(25.5) 
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Tab.No.28:- Chi square test risk score Vs Hypertension 
RISK ASSESSMENT 
Hypertension Total 
p value Yes,  
n (%) 
No,  
n(%) 
n (%) 
Q-RISK 
ASSESSMENT 
<10 0 0 0 
0.606 
10-20 7(6.9) 7(6.9) 14(13.7) 
21-30 9(8.9) 21(20.6) 30(29.4) 
31-40 11(10.9) 19(18.5) 30(29.4) 
≥40 9(8.9) 19(18.5) 28(27.5) 
WHO SCALE 
RISK 
ASSESSMENT 
<10 0 1(0.9) 1(0.9) 
0.692 
10-20 9(8.9) 13(12.7) 22(21.7) 
21-30 8(7.8) 22(21.6) 30(29.4) 
31-40 8(7.8) 11(10.9) 19(18.6) 
≥40 11(10.9) 19(18.5) 30(29.4) 
FRAMINGHAMS 
RISK 
ASSESSMENTT 
<10 0 0 0 
0.825 
10-20 7(6.9) 9(8.9) 16(15.7) 
21-30 8(7.8) 19(18.6) 27(26.4) 
31-40 12(11.8) 21(20.5) 33(32.4) 
≥40 9(8.9) 17(16.6) 26(25.5) 
 
  
results 
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Tab.No.29:- Chi square test risk score Vs stages of kidney disease 
RISK ASSESSMENT 
Stage of kidney disease Total 
p 
value 
Stage 1, 
n (%) 
Stage2, 
n(%) 
Stage 
3, n(%) 
Stage 
4,n(%) 
Stage 
5,n(%) 
n (%) 
Q-RISK 
ASSESSMENT 
<10 0 0 0 0 0 0 
0.133 
10-20 0 0 4(3.9) 4(3.9) 6(5.9) 14(13.7) 
21-30 2(1.9) 1(0.9) 6(5.9) 10(9.8) 11(10.9) 30(29.4) 
31-40 0 1(0.9) 7(6.9) 6(5.9) 16(15.7) 30(29.4) 
≥40 0 3(2.9) 9(8.9) 12(11.8) 4(3.8) 28(27.5) 
WHO SCALE 
RISK 
ASSESSMENT 
<10 0 0 0 1(0.9) 0 1(0.9) 
0.609 
10-20 0 0 7(6.9) 7(6.9) 8(7.8) 22(21.7) 
21-30 1(0.9) 1(0.9) 6(5.9) 8(7.8) 14(13.9) 30(29.4) 
31-40 1(0.9) 1(0.9) 3(2.9) 5(4.9) 9(8.9) 19(18.6) 
≥40 0 3(2.9) 10(9.8) 11(10.9) 6(5.9) 30(29.4) 
FRAMINGHA
MS RISK 
ASSESSMENT 
<10 0 0 0 0 0 0 
0.144 
10-20 0 0 4(3.9) 7(6.9) 5(4.9) 16(15.7) 
21-30 1(0.9) 0 7(6.9) 7(6.9) 12(11.8) 27(26.4) 
31-40 0 1(0.9) 8(7.9) 8(7.9) 16(15.7) 33(32.4) 
≥40 1(0.9) 4(3.9) 7(6.9) 10(9.8) 4(3.9) 26(25.5) 
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8. DISCUSSION 
 
Cardiovascular morbidity and mortality in patients with chronic kidney disease 
(CKD) is high, and the presence of CKD worsens outcomes of cardiovascular disease (CVD). 
The study done by Nathan R .et al
11
 on global prevalence of kidney disease was 13.4%. The 
current study shows a prevalence of 6.1 %. The study also revealed that male population is 
predominant and there were 59 males and 43 females among the study population. Various 
studies have mentioned about the predominance of male population for cardiovascular risk
11
. 
This study also shows that majority of study population’s age was 65-74 years (new elderly 
old) and this category is more prone to cardiovascular disease and also studies report that age 
is another important non-modifying risk factor for CVD. Another modifiable risk factor is 
BMI and the assessment revealed that only 20% of the study population were found to be 
above the normal. The assessment on the smoking or use of tobacco revealed that the 
majority were found to be non-smokers and those were smoking were found in high risk 
category. The minimum length of stay in the hospital was found to 2 and when number of 
days of stay increases it may increase the cost of the treatment the patient. The average 
number of days of hospital stay was found to be 5.47 ± 2.64days. The assessment of reasons 
for admission to the study site revealed that majority patientswere admitted for breathing 
difficulty and swelling of limbs which were a classical symptom for CKD and also indicate a 
high risk to cardiovascular disease. The past medical and medication history of study 
population revealed that they were having diabetes mellitus and hypertension  which are risk 
factors for diseases and the same is also which is cited in works done by Cláudia Bernardi et 
al.
27 
 
Family history of the patient having diabetes mellitus, systemic hypertension, chronic 
kidney disease are a non-modifying risk factor for CVD. The study report shows that 33% is 
having diabetes mellitus in their family history. The diagnosis of the study population also 
had revealed that majority of the population was having one or more modifying risk factors 
like Systemic Hypertension, Diabetes Mellitus and Chronic/Acute Kidney diseases. The 
present study also had variety of drugs prescribed respectively to the diseases condition of the 
study population and those drugs includes anti-hypertensives, proton pump inhibitors, 
diuretics, anti-lipidemic, anti-anginal, vitamin supplements, anti-epileptics, sedatives, anti-
discussion 
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inflammatory, antibiotics, etc. The average number of drugs prescribed was found to 
be8.009±2.852. The maximum number of drugs given to patient is 14 and minimum is 3. 
The use of drugs to control the elevated condition which may pose a risk to cardiovascular 
system may reduce the risk of getting CVD. Various route of administration was preferred in 
geriatric patients. Oral route was the most preferred route of administration used for study 
population use followed by 83.33% injections drugs which may increase the cost of the 
treatment and also invites other complications associated with injectable and this may be 
because some cases non-availability of drugs likes aminoglycosides as oral dosage forms, 
patient comfort and rapid action. There was about 22.64% of total drug prescribed as 
injectable. In some situations switching from IV drugs to oral allow reduction in the hospital 
stay and potential benefits which reduces hospitalization costs and other related costs. The 
analysis of stages of CKD revealed that 48.03% patients were under stage III whereas the 
global prevalence of stage 3 was 7.6%
11
.The very high prevalence in stage 3 patient may be 
because the patients were getting diagnosed and admitted to the hospital when the conditions 
were worsen and by the time patients were in stage 3 or stage 4. It was also found that the 
30.39% were on haemodialysis because patients in stage 4 and stage 5 of CKD needs dialysis 
or kidney transplantation. 
  
The prescription generated for the study population was analysed for any kind of drug 
related problems including drug dosage adjustments, medication error and ADR monitoring, 
drug-drug interactions, etc. The results revealed that only 2 incidence where drug dosage 
adjustment for renal insufficient patient was reported and .there was about 4 incidences where 
drug was prescribed without any indication and 4 incidences drug is required for indication. 
There were about 70 incidence of drug – drug interaction which account for 21 types of 
interactions including 6 major, 13 moderate and 2 minor interactions. The average number of 
drug-drug interactions was found to be 0.6568±0.969 
 
The risk assessment using WHO scale has revealed that females of the study 
population were found to be more in risk categories of 10-20% and 21-30% than their male 
counterparts. The assessment of the study population using QRISK calculators also revealed 
that females were predominant than males. The risk categories include 10-20%, 20-30% and 
30-40%. A similar results was also obtained using Framingham’s risk score calculator. The 
statistical analysis of the risk scores obtained were correlated with non-modifiable risk factors 
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like age and gender, modifiable factors like presence of diabetes mellitus, hypertension and 
stages of kidney disease has revealed a significant relationship in most of the cases. This 
category of very high risk will result in fatal or non-fatal vascular events and hence 
monitoring of risk factors are required for every 3-6 months. The rest of the population were 
male dominant in all the assessment. The monitoring of risk factors is required once in 6- 12 
months and management with life style modifications. The patients were given counselling 
and appropriate interventions based on their risk category. The counselling/education given to 
the patient included life style modifications, diet modifications, awareness of intake of fats, 
salt, alcohol, fruits, vegetables, etc. Patients were also informed and made aware about 
reduction of  BMI, weight, the target blood pressure, blood glucose levels, smoking cessation 
if the patient is smoker and about the importance’s of being complaint to the physician’s 
prescription like taking the prescribed drug for diabetes mellitus, systemic hypertension, lipid 
lowering or for chronic/acute renal failure. 
 
If any individuals is at very high cardiovascular risk because they might had already 
experienced a cardiovascular event, or have very high levels of individual risk factors. Risk 
stratification is not necessary for making treatment decisions for these individuals, all of them 
need intensive lifestyle interventions and appropriate drug therapy. Risk prediction charts 
may tend to underestimate cardiovascular risk in such individuals, who include the following: 
 Patients with established angina pectoris, coronary heart disease, myocardial 
infraction, ischemic attacks, stroke, peripheral vascular disease. 
 Left ventricular hypertrophy or hypertensive retinopathy. 
 Individuals without established CVD who have a cholesterol ≥8 mmol/l or LDL 
cholesterol ≥6mmol/l 
 Individuals  without established CVD who have persistent raised blood 
pressure(>160-170/100-105 mmHg) 
 Patients with type 1 and type 2 diabetes, with over nephropathy or other significant 
renal disease. 
 Patients with known renal failure or renal impairment. 
 
prevention of cardiovascular disease 
 
Assessment and Prevention of Risk for Development of Cardiovascular Diseases in Geriatric Population with Chronic 
Kidney Disease  
61 
 
 
9. PREVENTION OF CARDIOVASCULAR DISEASE 
 
 Dietary change, weight control, avoidance of cigarettes and treatment of hypertension 
can favourably influence the risk profile of the elderly. Although no randomized 
controlled trials have been performed on modification of risk factors in the elderly 
except for hypertension, optimism as to likely efficacy is justified. 
 
 Control of dyslipidemia, obesity and diabetes. Serum total and low density lipoprotein 
cholesterol can be lowered by decreased intake of cholesterol and saturated fat, with 
partial replacement of the saturated fat by polyunsaturated fat from vegetable and fish 
sources, by increased intake of water-soluble fiber and by reduction of overweight. 
Recent studies have shown a relation between the quantity and character of dietary 
fats, including fish oils, and coronary heart disease mortality. At least two recently 
completed controlled trials in younger populations have shown that reducing serum 
cholesterol by diet and drugs can lower coronary morbidity and mortality. The fat-
modified diets required are nutritionally adequate, safe, convenient, inexpensive and 
palatable. Obesity aggravates all atherogenic traits in both young and old. Weight 
control with a well-balanced fat-modified diet is a major hygienic approach for 
improving all the atherogenic risk factors in young and old people. Preventive 
measures for the elderly diabetic at high risk for cardiovascular disease should include 
reduction of overweight; control of elevated blood pressure by dietary and, if needed, 
drug therapy; control of  blood lipids and avoidance of cigarette smoking, in addition 
to control of blood sugar. 
 
 Cigarette smoking. It is likely that smoking contributes to thrombotic occlusion and is 
a risk factor for occlusive peripheral arterial disease in the elderly. Cigarette smoking 
is also a major contributor to chronic bronchitis, emphysema and lung cancer in the 
elderly. Regular physical activity. This should be encouraged in the elderly because 
overall and cardiovascular mortality rates apparently are benefited at all ages, 
including the elderly. 
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 Control of hypertension. Hypertension is a major remediable risk factor for 
cardiovascular disease in the elderly because of its high prevalence and sustained 
impact in advanced age. Hypertension control should lessen the incidence of stroke, 
cardiac failure and renal insufficiency. Although the efficacy of correcting isolated 
systolic hypertension has not been demonstrated, its impact on risk in the elderly is 
established, early experience with its treatment is encouraging and a full-scale 
controlled trial is underway. 
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10. SUMMARY 
The study entitled “Assessment and Prevention of risk for development of 
Cardiovascular diseases in Geriatric population with Chronic kidney disease” was 
carried out for a period of 10 months (December 2015 – September 2016). In this study, the 
data were collected from patients of the geriatric department of a private corporate tertiary 
care teaching hospital, during the ward rounds, as per the inclusion / exclusion criteria. The 
study carried out to assess the risk for cardiovascular events in patients with chronic kidney 
disease. The results obtained from the study may be summarized as follows: 
 A total of 102 patients were enrolled in the study. 
 The  total number of patients admitted in hospital was found to be 1667 and 102 
among were geriatric population with CKD who had been included in the study. 
 The study results revealed that a predominant male population of 57.84% was 
observed among the study population. 
 Age distribution of the study population was analyzed and it was found that 85.29% 
were in the age group 65-74 years in which males were 89.83% and females 79.06% 
 The BMI results reveals that 79.40% were very well normal and do not have the risk 
 It was found that 55.87% of study population had a stay of minimum 6  days in the 
hospital 
 The analysis of reasons for admission to the study site had revealed that certain 
complaints like difficulty in breathing, vomiting, swelling of limbs, decreased urine 
output etc., were found to be very common 
 Past medical history results revealed that diabetes mellitus, chronic renal failure and 
hypertension were very prevalent among the study population.  
 The individual habit of taking of alcohol and tobacco becomes an important risk 
factor for most of clinical condition. In this regard 79.4%of study population didn’t 
have the risk of having cardiovascular risk because they do not have the habit of 
smoking or drinking of alcohol. 
 Laboratory investigation result had revealed that electrolytes serum creatinine, urea 
and GFR were commonly assessed to most of the study population as it have included 
CRF patients. 
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 Diagnosis results revealed that the modifying variable risk factors other than CRF, 
systemic hypertension, diabetes mellitus and renal failure were also very prevalent 
among the study population 
 Drug categories analysis revealed that majority of the study population has received 
anti-hypertensive and antibiotics and proton pump inhibitors and almost majority of 
population has received one or more vitamin supplements. The average was found to 
be 8.009±2.852. The maximum number of drugs given to patient is 14 and minimum 
is 3 
 Route of administration result revealed that 83.33% of the drugs patients received 
were administrated as injections. 
 The various stages of kidney disease is analysed and it was found that 48.03% 
population belongs to stage III. 
 The analysis of drug-drug interactions prevailing in the prescriptions of study 
population had revealed that 44.11% of prescriptions were having one or more 
interaction and rest 55.88% didn’t have even one drug-drug interaction. There were 
about 21 drug-drug interactions prevailing in the prescriptions of study population 
which account of a drug – drug interaction. The  average was found to be  
0.6568±0.969 
 QRISK  scale had revealed that 29.41% of the study population were been categorised 
in the risk level of ≥40% in which 42.37% were males and 11.6% were females 
 Framinghams risk score was found that 24.50% of population were at high risk in 
which males were 37.28% and females were 9.93% 
 WHO charts results had revealed that 28.43% of the study population were been 
categorised in the risk level of ≥40% in which 33.89% were males and 4.65% were 
females. An overall 4.90% study population only were having risk of level less than 
10%.  
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11. CONCLUSION 
 
The study was carried out to assess the cardiovascular risk in geriatric patients, to 
provide prevention strategy for events in patients with chronic kidney disease, to assess the 
prescription patterns. The study concluded that there was an increased cardiovascular risk in 
geriatric patients with chronic kidney diseases. The study revealed that the male population in 
the study site were at greater risk and hypertension, diabetes mellitus as the major risk factor 
for cardiovascular disease. It was also concluded that use of QRISK calculator which do not 
require cholesterol assessment to calculate the cardiovascular risk can be made as a routine 
practice to assess and provide adequate prevention strategies of cardiovascular risk. 
Guidelines can be followed for the prevention and management of cardiovascular risk like by 
improving dietary intake, physical activity, weight control, life style advice etc. and also by 
providing awareness to the public by conducting health and nutrition education programs, 
and screening for early detection of cardiovascular disease. This study also revealed the 
importance of clinical pharmacist and their importance in providing pharmaceutical care to 
the patient for a better prognosis. 
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12. FUTURE OUTLOOK 
 
The study may be extended to a large population and it shall be carried out to focus on 
safe and effective management of chronic kidney disease and cardiovascular risk in geriatric 
population, along with patient’s awareness program which may be created and impact of the 
same may be also studied. 
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1 WHO/ISH Risk prediction charts
for 14 WHO epidemiological sub-regions
1. Introduction
2.  Instructions on how to use WHO/ISH (World Health Organization/International Society of 
hypertension) risk prediction charts
3. Africa WHO sub-regions AFR D, AFR E
Charts in colour for use in settings where 
total blood cholesterol can be measured
Figure 1. WHO/ISH risk prediction chart for AFR D
Figure 2. WHO/ISH risk prediction chart for AFR E
Charts in colour for use in settings where 
total blood cholesterol cannot be measured
Figure 3. WHO/ISH risk prediction chart for AFR D
Figure 4. WHO/ISH risk prediction chart for AFR E
4. The Americas WHO sub-regions AMR A, AMR B, AMR D 
Charts in colour for use in settings where 
total blood cholesterol can be measured
Figure 5. WHO/ISH risk prediction chart for AMR A
Figure 6. WHO/ISH risk prediction chart for AMR B
Figure 7. WHO/ISH risk prediction chart for AMR D
Charts in colour for use in settings where 
total blood cholesterol cannot be measured
Figure 8. WHO/ISH risk prediction chart for AMR A
Figure 9. WHO/ISH risk prediction chart for AMR B
Figure 10. WHO/ISH risk prediction chart for AMR D
5. Eastern Mediterranean WHO sub-regions EMR B, EMR D 
Charts in colour for use in settings where 
total blood cholesterol can be measured
Figure 11. WHO/ISH risk prediction chart for EMR B
Figure 12. WHO/ISH risk prediction chart for EMR D
Charts in colour for use in settings where 
total blood cholesterol cannot be measured
Figure 13. WHO/ISH risk prediction chart for EMR B
Figure 14. WHO/ISH risk prediction chart for EMR D
6. Europe WHO sub-regions EUR A, EUR B, EUR C
Charts in colour for use in settings where 
total blood cholesterol can be measured
Figure 15. WHO/ISH risk prediction chart for EUR A
Figure 16. WHO/ISH risk prediction chart for EUR B
Figure 17. WHO/ISH risk prediction chart for EUR C
Charts in colour for use in settings where 
total blood cholesterol cannot be measured
Figure 18. WHO/ISH risk prediction chart for EUR A
Figure 19. WHO/ISH risk prediction chart for EUR B
Figure 20. WHO/ISH risk prediction chart for EUR C
7. South East Asia WHO sub-regions SEAR B, SEAR D
Charts in colour for use in settings where 
total blood cholesterol can be measured
Figure 21. WHO/ISH risk prediction chart for SEAR B
Figure 22. WHO/ISH risk prediction chart for SEAR D
Charts in colour for use in settings where 
total blood cholesterol cannot be measured
Figure 23. WHO/ISH risk prediction chart for SEAR B
Figure 24. WHO/ISH risk prediction chart for SEAR D
8. Western Pacific WHO sub-regions WPR A, WPR B
Charts in colour for use in settings where 
total blood cholesterol can be measured
Figure 25. WHO/ISH risk prediction chart for WPR A
Figure 26. WHO/ISH risk prediction chart for WPR B
Charts in colour for use in settings where 
total blood cholesterol cannot be measured
Figure 27. WHO/ISH risk prediction chart for WPR A
Figure 28. WHO/ISH risk prediction chart for WPR B
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1. Introduction
These charts indicate 10-year risk of a fatal or non-fatal major cardiovascular event 
(myocardial infarction or stroke), according to age, sex, blood pressure, smoking 
status, total blood cholesterol and presence or absence of diabetes mellitus for 14 WHO 
epidemiological sub-regions. 
There are two sets of charts. One set can be used in settings where blood cholesterol can 
be measured. The other set is for settings in which blood cholesterol cannot be measured. 
Both sets are available according to the 14 WHO epidemiological sub-regions. 
Each chart can only be used in countries of the specific WHO epidemiological sub-region, 
e.g. The charts for South East Asia sub-region B (SEAR B) can only be used in Indonesia, 
Sri Lanka and Thailand. 
The list of WHO/ISH risk prediction charts by epidemiological sub-regions and the Member 
States in which they can be used are shown in table 1. 
WHO/ISH Risk prediction charts
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Table 1. List of WHO/ISH risk prediction charts by epidemiological sub-regions1 and 
WHO Member States 
WHO/ISH risk prediction 
charts by epidemiological 
sub-regions
WHO Member States
Africa AFR D Algeria, Angola, Benin, Burkina Faso, Cameroon, Cape Verde, Chad, Comoros,  
Equatorial Guinea, Gabon, Gambia, Ghana, Guinea, Guinea-Bissau, Liberia,  
Madagascar, Mali, Mauritania, Mauritius, Niger, Nigeria, Sao Tome And Principe,  
Senegal, Seychelles, Sierra Leone, Togo
AFR E Botswana, Burundi, Central African Republic, Congo, Côte d’Ivoire,  
Democratic Republic of The Congo, Eritrea, Ethiopia, Kenya, Lesotho, Malawi,  
Mozambique, Namibia, Rwanda, South Africa, Swaziland, Uganda,  
United Republic of Tanzania, Zambia, Zimbabwe
The Americas AMR A Canada*, Cuba, United States of America*
AMR B Antigua and Barbuda, Argentina, Bahamas, Barbados, Belize, Brazil, Chile, 
Colombia, Costa Rica, Dominica, Dominican Republic, El Salvador, Grenada, 
Guyana, Honduras, Jamaica, Mexico, Panama, Paraguay, Saint Kitts And Nevis, 
Saint Lucia, Saint Vincent and The Grenadines, Suriname, Trinidad and Tobago, 
Uruguay, Venezuela
AMR D Bolivia, Ecuador, Guatemala, Haiti, Nicaragua, Peru
Eastern 
Mediterranean 
 
EMR B Bahrain, Iran (Islamic Republic of), Jordan, Kuwait, Lebanon, Libyan Arab 
Jamahiriya, Oman, Qatar, Saudi Arabia, Syrian Arab Republic, Tunisia, United 
Arab Emirates
EMR D Afghanistan, Djibouti, Egypt, Iraq, Morocco, Pakistan, Somalia, Sudan, Yemen
Europe* EUR A Andorra, Austria, Belgium, Croatia, Cyprus, Czech Republic, Denmark, Finland, 
France, Germany, Greece, Iceland, Ireland, Israel, Italy, Luxembourg, Malta, 
Monaco, Netherlands, Norway, Portugal, San Marino, Slovenia, Spain, Sweden, 
Switzerland, United Kingdom
EUR B Albania, Armenia, Azerbaijan, Bosnia And Herzegovina, Bulgaria, Georgia, 
Kyrgyzstan, Poland, Romania, Serbia and Montenegro, Slovakia, Tajikistan,  
The Former Yugoslav Republic of Macedonia, Turkey, Turkmenistan, Uzbekistan
EUR C Belarus, Estonia, Hungary, Kazakhstan, Latvia, Lithuania, Republic of Moldova,  
Russian Federation, Ukraine
South-East 
Asia
SEAR B Indonesia, Sri Lanka, Thailand
SEAR D Bangladesh, Bhutan, Democratic People’s Republic of Korea, India, Maldives,  
Myanmar, Nepal
Western  
Pacific
WPR A Australia*, Brunei Darussalam, Japan, New Zealand*, Singapore
WPR B Cambodia, China, Cook Islands, Democratic People’s Republic of Korea, 
Fiji, Kiribati, Lao People’s Democratic Republic, Malaysia, Marshall Islands, 
Micronesia (Federated States of), Mongolia, Nauru, Niue, Palau,  
Papua New Guinea, Philippines, Samoa, Solomon Islands, Tonga, Tuvalu, 
Vanuatu, Viet Nam
1 Mortality strata: A: very low child mortality and very low adult mortality; B: low child mortality and low 
adult mortality; C: low child mortality and high adult mortality; D: high child mortality and high adult 
mortality; E: high child mortality and very high adult mortality.
* Appropriate risk prediction charts already available 
WHO/ISH Risk prediction charts
for 14 WHO epidemiological sub-regions
4
2.  Instructions on how to use WHO/ISH  
(World Health Organization/International 
Society of hypertension) risk prediction charts
The charts provide approximate estimates of cardiovascular disease (CVD) risk in people 
who do not have established coronary heart disease, stroke or other atherosclerotic 
disease. They are useful as tools to help identify those at high cardiovascular risk, and 
to motivate patients, particularly to change behaviour and, when appropriate, to take 
antihypertensive, lipid-lowering drugs and aspirin. 
How do you use the charts to assess cardiovascular risk? 
First make sure that you select the appropriate charts using information in table 1  ■
If blood cholesterol cannot be measured due to resource limitations, use the charts  ■
that do not have total cholesterol 
Before applying the chart to estimate the 10-year cardiovascular risk of an individual,  ■
the following information is necessary 
Presence or absence of diabetes • 1
Gender  •
Smoker or non-smoker  •
Age  •
Systolic blood pressure • 2
Total blood cholesterol (if in mg/dl divide by 38 to convert to mmol/l) •
Once the above information is available proceed to estimate the 10-years cardiovascular 
risk as follows. 
Step 1 Select the appropriate chart depending on the presence or absence of diabetes1 
Step 2 Select male or female tables 
Step 3 Select smoker or non smoker boxes3
Step 4  Select age group box (if age is 50-59 years select 50, if 60-69 years select 60 
etc) 
Step 5  Within this box find the nearest cell where the individuals systolic blood 
pressure (mm Hg) and total blood cholesterol level (mmol/l)4 cross. The colour of 
this cell determines the 10-year cardiovascular risk. 
1.  A person who has diabetes is defined as someone taking insulin or oral hypoglycaemic drugs, or with a fasting plasma 
glucose concentration above 7.0 mmol/l (126 mg/dl) or a postprandial (approximately 2 hours after a main meal) plasma 
glucose concentration above 11.0 mmol/l (200 mg/l)on two separate occasions). For very low resource settings urine sugar 
test may be used to screen for diabetes if blood glucose assay is not feasible. If urine sugar test is positive a confirmatory 
blood glucose test need to be arranged to diagnose diabetes mellitus. 
2.  Systolic blood pressure, taken as the mean of two readings on each of two occasions, is sufficient for assessing risk but not 
for establishing a pretreatment baseline.
3.  All current smokers and those who quit smoking less than 1 year before the assessment are considered smokers for assess-
ing cardiovascular risk. 
4.  The mean of two non-fasting measurements of serum cholesterol by dry chemistry, or one non-fasting laboratory measure-
ment, is sufficient for assessing risk. 
WHO/ISH Risk prediction charts
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Practice points
Please note that CVD risk may be higher than indicated by the charts in the presence of 
the following:
already on antihypertensive therapy ■
premature menopause ■
approaching the next age category or systolic blood pressure category ■
obesity (including central obesity); ■
sedentary lifestyle; ■
family history of premature coronary heart disease (CHD) or stroke in first degree  ■
relative (male < 55 years, female < 65 years); 
raised triglyceride level (>2.0 mmol/l or 180 mg/dl); ■
low HDL (high density lipoprotein) cholesterol level (< 1 mmol/l or 40mg/dl in males, <  ■
1.3 mmol/l or 50 mg/dl in females);
raised levels of C-reactive protein, fibrinogen, homocysteine, apolipoprotein B or Lp(a),  ■
or fasting glycaemia, or impaired glucose tolerance; 
microalbuminuria (increases the 5-year risk of diabetics by about 5%) (38, 83, 85); ■
raised pulse rate.  ■
socioeconomic deprivation ■
Risk levels 
The colour of the cell indicates the 10-year risk of combined myocardial infarction and 
stroke risk (fatal and non-fatal) as shown below. 
10-year combined myocardial infarction and stroke risk (fatal and non-fatal)
■ Green  <10%
■ Yellow 10% to <20%
■ Orange 20% to <30%
■ Red 30% to <40%
■ Deep Red > 40%
WHO/ISH Risk prediction charts
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7. South East Asia
WHO sub-regions SEAR B, SEAR D 
Charts in colour for use in settings where total blood cholesterol can be measured
 Figure 21. WHO/ISH risk prediction chart for SEAR B
 Figure 22. WHO/ISH risk prediction chart for SEAR D
Charts in colour for use in settings where total blood cholesterol cannot be measured
 Figure 23. WHO/ISH risk prediction chart for SEAR B
 Figure 24. WHO/ISH risk prediction chart for SEAR D
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Figure 21. WHO/ISH risk prediction chart for SEAR B. 10-year risk of a fatal or non-fatal 
cardiovascular event by gender, age, systolic blood pressure, total blood cholesterol, smoking 
status and presence or absence of diabetes mellitus. 
SEAR B People with Diabetes Mellitus
Age 
(years)
Male Female SBP
(mm Hg)Non-smoker Smoker Non-smoker Smoker
70
180
160
140
120
60
180
160
140
120
50
180
160
140
120
40
180
160
140
120
4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8
Cholesterol (mmol/l)
Risk Level <10% 10% to <20% 20% to <30% 30% to <40% ≥40%
SEAR B People without Diabetes Mellitus
Age 
(years)
Male Female SBP
(mm Hg)Non-smoker Smoker Non-smoker Smoker
70
180
160
140
120
60
180
160
140
120
50
180
160
140
120
40
180
160
140
120
4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8
Cholesterol (mmol/l)
This chart can only be used for countries of the WHO Region of South-East Asia,  
sub-region B, in settings where blood cholesterol can be measured. (see Table 1)
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Figure 22. WHO/ISH risk prediction chart for SEAR D. 10-year risk of a fatal or non-fatal 
cardiovascular event by gender, age, systolic blood pressure, total blood cholesterol, smoking 
status and presence or absence of diabetes mellitus. 
SEAR D People with Diabetes Mellitus
Age 
(years)
Male Female SBP
(mm Hg)Non-smoker Smoker Non-smoker Smoker
70
180
160
140
120
60
180
160
140
120
50
180
160
140
120
40
180
160
140
120
4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8
Cholesterol (mmol/l)
Risk Level <10% 10% to <20% 20% to <30% 30% to <40% ≥40%
SEAR D People without Diabetes Mellitus
Age 
(years)
Male Female SBP
(mm Hg)Non-smoker Smoker Non-smoker Smoker
70
180
160
140
120
60
180
160
140
120
50
180
160
140
120
40
180
160
140
120
4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8
Cholesterol (mmol/l)
This chart can only be used for countries of the WHO Region of South-East Asia,  
sub-region D, in settings where blood cholesterol can be measured (see Table 1).
WHO/ISH Risk prediction charts
for 14 WHO epidemiological sub-regions
33
Figure 23. WHO/ISH risk prediction chart for SEAR B. 10-year risk of a fatal or non-fatal 
cardiovascular event by gender, age, systolic blood pressure, smoking status and presence or 
absence of diabetes mellitus. 
SEAR B People with Diabetes Mellitus
Age 
(years)
Male Female
SBP
(mm Hg)Non-smoker Smoker Non-smoker Smoker
70
180
160
140
120
60
180
160
140
120
50
180
160
140
120
40
180
160
140
120
Risk Level <10% 10% to <20% 20% to <30% 30% to <40% ≥40%
SEAR B People without Diabetes Mellitus
Age 
(years)
Male Female
SBP
(mm Hg)Non-smoker smoker Non-smoker smoker
70
180
160
140
120
60
180
160
140
120
50
180
160
140
120
40
180
160
140
120
4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8
This chart can only be used for countries of the WHO Region of South-East Asia,  
sub-region B, in settings where blood cholesterol CANNOT be measured (see Table 1).
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Figure 24. WHO/ISH risk prediction chart for SEAR D. 10-year risk of a fatal or non-fatal 
cardiovascular event by gender, age, systolic blood pressure, smoking status and presence or 
absence of diabetes mellitus. 
SEAR D People with Diabetes Mellitus
Age 
(years)
Male Female
SBP
(mm Hg)Non-smoker Smoker Non-smoker Smoker
70
180
160
140
120
60
180
160
140
120
50
180
160
140
120
40
180
160
140
120
Risk Level <10% 10% to <20% 20% to <30% 30% to <40% ≥40%
SEAR D People without Diabetes Mellitus
Age 
(years)
Male Female
SBP
(mm Hg)Non-smoker smoker Non-smoker smoker
70
180
160
140
120
60
180
160
140
120
50
180
160
140
120
40
180
160
140
120
4 5 6 7 8 4 5 6 7 8 4 5 6 7 8 4 5 6 7 8
This chart can only be used for countries of the WHO Region of South-East Asia,  
sub-region D, in settings where blood cholesterol CANNOT be measured. (see Table 1)
